Conditions: Pulmonary Arterial Hypertension
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 45
Healthy volunteers: no

Brief summary:
This study was an open-label extension study to determine the long-term safety and tolerability of ralinepag in subjects with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) who have completed Study APD811-003, or who were assigned to receive placebo and were discontinued due to clinical worsening.

Detailed description:
This study was an open-label extension study to determine the long-term safety and tolerability of ralinepag in subjects with WHO Group 1 PAH who completed Study APD811-003. Subjects who completed Study APD811-003 and met eligibility criteria for Study APD811-007 were enrolled. Additionally, placebo-treated subjects who discontinued study drug treatment due to clinical worsening in Study APD811-003 were permitted to enroll in Study APD811-007, upon approval of the medical monitor, provided that all end of study procedures including right heart catheterization (RHC) were performed per the study protocol. The Week 25 Visit in Study APD811-003 served as the Baseline Visit for Study APD811-007.

All subjects enrolled in Study APD811-007 received open-label treatment with ralinepag. The starting dose and titration schedule were individually determined and in accordance with the starting dose and titration schedule optimized from Study APD811-003. Adjustments in the dose and titration schedule were made according to subject tolerability.

After an individual subject completed Study APD811-003 and that subject's database was locked, subject unblinding occurred. Subjects on active treatment (ralinepag) remained on their current dose and had onsite clinical assessments performed every 3 months until the subject was discontinued from the study.

Subjects in the placebo treatment group underwent a dose titration period until a stable, maximum tolerated dose (MTD) was reached (up to 9 weeks), followed by a treatment period after the MTD was determined during which monthly onsite clinic assessments were performed for the first 3 months and then every 3 months until the subject was discontinued from the study or the study was terminated. Dose reductions could be made at any time for safety reasons. Incremental dose increases were also allowed during the Treatment Period at the discretion of the Investigator (as clinically indicated) and according to the stepwise titration scheme.

Subjects were assessed for clinical worsening during each clinic visit. If clinical worsening was confirmed, the Investigator could have opted to either continue treatment with ralinepag at the current dose, increase the dose of ralinepag, interrupt treatment, or discontinue the subject at his/her discretion.

In addition, attempts were made to contact all subjects at the time of Study APD811-007 termination to assess their vital (mortality) status. After the last subject enrolled in Study APD811-007 completed approximately 6 months of the study, a cumulative all-subject data analysis was performed for all subjects who entered the study. Subjects continued to have visits to the clinic every 3 months until the Sponsor discontinued the study. At the time of the Sponsor's decision to discontinue the study, all ongoing subjects completed an End of Study Visit. A 28-day Follow-up Visit was conducted to ensure appropriate subject safety. Subjects who remained on ralinepag were eligible to transition into the Phase 3 open-label extension study (ROR-PH-303) prior to APD811-007 study termination. For those subjects that did not enroll in Study ROR-PH-303, a 28-day Follow-up Visit was conducted to evaluate ongoing subject safety, including survival status.

Arms:
arm 1: Ralinepag immediate-release (IR) capsules of 10, 20, 30, 40, and 100 mcg or extended-release (XR) tablets of 50, 250, and 400 mcg for oral administration.

Interventions: intervention 1: Ralinepag
Intervention descriptions: intervention 1: Active

Protocol document:
Prot_000.pdf: 
United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
CONFIDENTIAL AND PROPRIETARY, UNITED THERAPEUTICS 
CORPORATION 
All content contained herein is confidential and proprietary information of United 
Therapeutics Corporation and shall not be disclosed in whole or in part except as permitted by 
a signed contract with United Therapeutics Corporation. © 2019 United Therapeutics 
Corporation 
 
Page 1 
 
Study Protocol 
Number: 
APD811-007 
Study Title: 
An Open-label Extension Study of APD811-003 in Patients with 
Pulmonary Arterial Hypertension 
Study Phase: 
2 
Product Name: 
Ralinepag (APD811) 
IND Number: 
109021 
Indication: 
Pulmonary Arterial Hypertension 
Investigators: 
Multicenter 
Sponsor: 
United Therapeutics Corporation  
Sponsor Contact: United Therapeutics Corporation  
55 T.W. Alexander Drive  
Research Triangle Park, NC 27709 
USA 
 
 
 
 Date 
Original Protocol: 17 June 2014 
Amendment 01: 15 August 2014 
Amendment 02: 09 October 2017 
Amendment 03: 04 Jun 2018 
Amendment 04: 15 May 2019 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 2 
LIST OF CONTACTS FOR THE STUDY 
Contract Research 
Organizations 
 
 
 
 
 
Study Sponsor 
 
United Therapeutics Corporation 
55 TW Alexander Dr 
Research Triangle Park, NC 27709  
USA 
SAE Reporting 
United Therapeutics Global Drug Safety 
Global Fax
  
email: 
  
 
Clinical Laboratory 
 
 
 
 
ECG  
 
 
 
 
 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 3 
INVESTIGATOR’S AGREEMENT 
I have read the attached protocol entitled “An Open-label Extension Study of APD811-003 in 
Patients with Pulmonary Arterial Hypertension” Amendment 4 dated 15 May 2019, and agree 
to abide by all provisions set forth therein. 
I agree to comply with the International Council for Harmonisation Guideline for Good 
Clinical Practice and applicable Food and Drug Administration regulations/guidelines set 
forth in 21 Code of Federal Regulations Parts 50, 54, 56, and 312 and local regulations per 
country. 
I agree to ensure that the confidential information contained in this document will not be used 
for any purpose other than the evaluation or conduct of the clinical investigation without the 
prior written consent of United Therapeutics Corporation. 
I also have read the current Investigator’s Brochure for ralinepag and acknowledge that 
review of the information contained in the Investigator’s Brochure is a requirement for 
Investigators before using ralinepag in a clinical study. 
This protocol has been received for information only and must not be implemented before all 
necessary regulatory agency and ethics approval documents have been obtained. 
 
 
 
 
Signature of Principal Investigator 
 
Date 
 
 
 
 
 
 
Printed Name of Principal Investigator 
 
 




United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 5 
Objectives: 
Primary: 
To evaluate the long-term safety and tolerability of ralinepag in 
subjects with World Health Organization (WHO) Group 1 
pulmonary arterial hypertension (PAH) who have completed Study 
APD811-003. 
Secondary: 
To evaluate the effect of ralinepag in subjects with WHO Group 1 
PAH who completed Study APD811-003, as determined by the 
incidence of clinical worsening.  Clinical worsening is defined as 
fulfillment of any 1 of the following criteria (as assessed by change 
from baseline in Study APD811-003): 
• Death, or onset of treatment-emergent adverse event (AE) 
with a fatal outcome occurring less than or equal to 14 days 
after study treatment discontinuation 
• Hospitalization for worsening PAH, heart-lung or lung 
transplant, or atrial septostomy 
• The subject requires the addition (or change in dose if 
applicable) of any of the following PAH-specific 
medications: 
• Prostacyclin/prostacyclin analogue (intravenous [IV], 
subcutaneous [SC], oral, or inhaled)  
• Phosphodiesterase type 5 inhibitor (PDE5-I) 
• Soluble guanylate cyclase stimulator (sGC) 
• Endothelin receptor antagonist 
• The combined occurrence of the events listed below:  
• A decrease in 6-Minute Walk Distance (6MWD) by at 
least 20% from baseline, confirmed on two 6-Minute 
Walk Tests (6MWTs), on different days 
• Increase (worsening) in WHO/New York Heart 
Association (NYHA) Functional Class (FC) from 
baseline 
• Appearance of or worsening of signs/symptoms of right 
heart failure that did not respond to optimized oral 
diuretic therapy. 
In cases of clinical deterioration, the Investigator must assess 
carefully if the deterioration of the subject’s condition (eg, 
worsening FC) is related to the underlying PAH or can be 
explained by an alternative cause (eg, transient infection, 
musculoskeletal disease, surgical or medical intervention other than 
pulmonary hypertension (PH) related, exacerbation of a 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 6 
concomitant lung disease, lacking compliance of medication 
intake).  Only persistent clinical deteriorations caused by the 
underlying PAH and confirmed as per the above criteria, will be 
considered clinical worsening. 
In subjects with WHO Group 1 PAH who have completed Study 
APD811-003, to evaluate changes from Baseline for the following 
efficacy endpoints with ralinepag treatment 
• 6MWD 
• WHO/NYHA FC 
• Hemodynamics 
Study Design: 
This protocol describes an open-label extension study to determine 
the long-term safety and tolerability of ralinepag in subjects with 
WHO Group 1 PAH who have completed the Phase 2 study, 
APD811-003.  Subjects must have completed Study APD811-003 
and must meet eligibility criteria for Study APD811-007.  
Additionally, placebo-treated subjects who discontinue ralinepag 
treatment due to clinical worsening in Study APD811-003 will be 
permitted to enroll in Study APD811-007 upon approval of the 
medical monitor, provided that all End of Study procedures, 
including right heart catheterization (RHC), are performed per 
protocol. 
The Week 25 Visit in Study APD811-003 will serve as the Baseline 
Visit for Study APD811-007.  If the Week 25 Visit for Study 
APD811-003 serves as the initial visit for Study APD811-007, 
subjects should be consented for Study APD811-007 prior to the 
final procedures being performed for Study APD811-003. 
All subjects enrolled in Study APD811-007 will receive open-label 
treatment with ralinepag.  The starting dose and titration schedule 
will be individually determined and in accordance with the starting 
dose and titration schedule optimized from Study APD811-003.  
Adjustments in the dose and titration schedule may be made 
according to subject tolerability. 
After an individual subject completes Study APD811-003 and that 
subject’s database is locked, subject unblinding will occur.  
Subjects on active treatment (ralinepag) will remain on current dose 
and have onsite clinical assessments performed every 3 months 
until the subject is discontinued from the study. 
Subjects in the placebo treatment group will undergo a Dose 
Titration Period until a stable, maximum tolerated dose (MTD) is 
reached (up to 9 weeks), followed by a Treatment Period after the 
MTD is determined, during which monthly onsite clinic 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 7 
assessments will be performed for the first 3 months and then every 
3 months until the subject is discontinued from the study or the 
study is terminated.  
Discontinuation of the study may also occur at the Sponsor’s 
decision to terminate the study.  Dose reductions may be made at 
any time for safety reasons. 
Incremental dose increases will also be allowed during the 
Treatment Period at the discretion of the Investigator (as clinically 
indicated) and according to the stepwise titration scheme. 
Subjects will be assessed for clinical worsening during each clinic 
visit.  If clinical worsening is confirmed, the Investigator may opt 
to either continue treatment with ralinepag at the current dose, 
increase the dose of ralinepag, interrupt treatment, or discontinue 
the subject at his/her discretion. 
In addition, all subjects will be contacted at the time of Study 
APD811-007 closure to assess vital (mortality) status.  The vital 
status follow-up contact of subjects will depend on local 
regulations or specific agreement with the subject and Investigator. 
After the last subject enrolled in Study APD811-007 has completed 
approximately 6 months of the study, a cumulative all-subject data 
analysis will be performed for all subjects who entered the study.  
Subjects will continue to have visits to the clinic every 3 months 
indefinitely to collect data until marketing approval of ralinepag is 
granted or until the Sponsor discontinues the study.  At the time of 
marketing approval or the Sponsor’s decision to discontinue the 
study, all ongoing subjects will complete an End of Study Visit.  A 
28-day Follow-up Visit will be conducted to ensure appropriate 
subject safety.  This visit may be conducted by telephone or in 
person based upon the Investigator’s discretion.  Subjects who 
remain on ralinepag at study termination and meet all eligibility 
criteria are eligible to roll into the open-label extension study 
(ROR-PH-303). 
Concomitant Medications 
Subjects are permitted oral disease-specific PAH therapy consisting 
of an ERA and/or a PDE5-I or sGC stimulator, but not all 3.  The 
on-study addition/substitution of an ERA, PDE5-I, or sGC 
stimulator, if on a single such agent at Baseline, or dosage increase 
for such agents is permitted.  In addition to ralinepag, subjects can 
be prescribed no more than 1 agent from the ERA class and 1 from 
the PDE5-I/sGC stimulator class at any 1 time.  Substitution and 
dose adjustment within each of these classes is permitted.  Subjects 
should be evaluated for the presence of clinical worsening if 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 8 
additional therapy or dose adjustments of current therapies are 
required. 
In addition, the following therapies, which may affect PAH, are 
permitted and doses may be adjusted as needed: 
• Vasodilators (including calcium channel blockers) 
• Digoxin 
• Spironolactone 
• L-Arginine supplementation 
Diuretics may be dosed as clinically indicated throughout the study. 
Subjects who require treatment with a prostacyclin/prostacyclin 
analogue (IV, SC, oral, or inhaled), except for acute vasodilator 
testing during cardiac catheterization, will be discontinued from the 
study.  
Study Site: 
Multiple centers in the United States, Europe, and Australia. 
Subject Population:  Subjects with WHO Group 1 PAH who have completed Study 
APD811-003 as planned and who meet eligibility criteria for Study 
APD811-007.  Additionally, placebo-treated subjects who 
discontinued study drug treatment due to clinical worsening in 
Study APD811-003 will be permitted to enroll in Study 
APD811-007, upon approval of the medical monitor, provided that 
all End of Study procedures, including RHC, are performed per 
protocol. 
All women, regardless of childbearing potential, must have a 
negative serum pregnancy test at Baseline.  
Males and females of childbearing potential must use adequate 
means of contraception and must agree not to participate in a 
conception process (ie, active attempt to become pregnant or to 
impregnate, sperm donation, in vitro fertilization) during the study 
and for 1 month after the last dose of study drug. 
Eligibility: 
Key Inclusion Criteria: 
• Evidence of a personally signed and dated informed 
consent document 
• Is willing and able to comply with scheduled visits, 
treatment plan, laboratory tests, and other study procedures 
and is deemed an appropriate candidate for participation in 
a long-term extension study and administration of ralinepag 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 9 
• Fulfilled all eligibility criteria for Study APD811-003 and 
completed the study as planned  
• Subjects who discontinued for clinical worsening in Study 
APD811-003 and were assigned to placebo and completed 
all End of Study procedures, including RHC, may 
participate after their data from Study APD811-003 are 
cleaned and locked 
Key Exclusion Criteria: 
• Subjects who enrolled in Study APD811-003 and were 
withdrawn from study drug treatment due to any AE, 
serious adverse event (SAE), or clinical worsening if 
assigned to ralinepag, or subjects who did not complete 
Study APD811-003 for other reasons. 
• Female subjects who wish to become pregnant 
• Systolic blood pressure <90 mmHg at Baseline/Day 1 
• Other severe acute or chronic medical or laboratory 
abnormality that may increase the risk associated with 
study participation or investigational product 
administration or may interfere with the interpretation of 
study results and, in the judgment of the Investigator, 
would make the subject inappropriate for entry into this 
study. 
Duration per 
Subject: 
Treatment with ralinepag will be indefinite until either marketing 
approval of ralinepag is granted or the Sponsor discontinues the 
study.  Subjects who remain on ralinepag at study termination and 
meet all eligibility criteria are eligible to roll into the open-label 
extension study (ROR-PH-303). 
Subject Assignment: All subjects will receive ralinepag 
Sample Size:  
Approximately 60 subjects 
Primary Outcome 
Measures: 
The primary endpoint for the study is long-term safety.  The safety 
of ralinepag will be monitored throughout the study with safety 
endpoints being as follows: 
• Treatment-emergent AEs up to 28 days following 
discontinuation of the study drug. 
• Treatment-emergent SAEs up to 28 days following 
discontinuation of the study drug. 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 10 
Efficacy Assessments: Efficacy will be assessed via performance of the following 
procedures: 
• 6MWT 
• WHO/NYHA FC assessment 
• Assessment of clinical worsening 
• Vital status 
• RHC  
Efficacy Endpoints: Assessment of time to clinical worsening and change from baseline 
in Study APD811-003 of the following: 
• 6MWD 
• WHO/NYHA FC 
• Hemodynamics 
Safety Assessments: 
• Clinical laboratory tests (to include hematology, 
coagulation parameters, serum chemistry, and urinalysis)  
• Vital signs 
• Physical examinations 
• 12-lead electrocardiograms (ECGs) 
• AEs 
Data Analyses: 
Long-term safety and tolerability of ralinepag will be assessed by 
clinical and statistical review of all relevant safety parameters, 
including AEs, laboratory values, vital signs, and ECGs.  All 
subjects who received at least 1 dose of ralinepag in this extension 
study will be included in the safety assessment. 
The time to clinical worsening will be summarized.  Estimation and 
95% confidence intervals for within-treatment change from 
baseline in 6MWD and WHO/NYHA FC assessment will also be 
performed.  Baseline is defined as the Day 1 pre-dose measurement 
from Study APD811-003.  A secondary analysis using a definition 
of Baseline as Day 1 of Study APD811-007 will also be performed. 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 11 
TABLE OF CONTENTS 
LIST OF CONTACTS FOR THE STUDY 
........................................................................2 
INVESTIGATOR’S AGREEMENT 
..................................................................................3 
SYNOPSIS 
...........................................................................................................................4 
TABLE OF CONTENTS .................................................................................................. 11
 
List of Appendices 
............................................................................................................. 14
 
Table of In-Text Tables 
..................................................................................................... 14
 
Table of In-Text Figures.................................................................................................... 14
 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
................................... 15
 
1 INTRODUCTION 
....................................................................................................... 17
 
1.1 BACKGROUND INFORMATION 
........................................................................ 21
 
1.1.1 
Rationale for Proposed Clinical Study .............................................................. 21
 
1.1.2 
Summary of Nonclinical Data 
............................................................................ 21
 
1.1.3 
Summary of Clinical Data 
.................................................................................. 22
 
1.2 ETHICS AND REGULATORY CONSIDERATIONS 
......................................... 26
 
2 STUDY OBJECTIVES 
................................................................................................ 27
 
2.1 PRIMARY OBJECTIVE 
........................................................................................ 27
 
2.2 SECONDARY OBJECTIVES 
................................................................................ 27
 
3 INVESTIGATIONAL PLAN 
...................................................................................... 27
 
3.1 OVERALL STUDY DESIGN AND PLAN 
............................................................ 27
 
3.2 RATIONALE FOR STUDY DESIGN ................................................................... 30
 
4 STUDY POPULATION SELECTION 
....................................................................... 35
 
4.1 STUDY POPULATION 
.......................................................................................... 35
 
4.2 INCLUSION CRITERIA ....................................................................................... 35
 
4.3 EXCLUSION CRITERIA ...................................................................................... 36
 
5 STUDY TREATMENTS 
............................................................................................. 36
 
5.1 TEST ARTICLE 
..................................................................................................... 36
 
5.2 TREATMENTS ADMINISTERED 
....................................................................... 37
 
5.3 PACKAGING, LABELING AND STORAGE 
...................................................... 37
 
5.4 TEST ARTICLE ACCOUNTABILITY ................................................................ 37
 
5.5 INVESTIGATIONAL PRODUCT RETENTION AT STUDY SITE 
................... 38
 
5.6 DOSAGE AND ADMINISTRATION 
.................................................................... 38
 
5.6.1 
Immediate-release Capsules 
............................................................................... 38
 
5.6.1.1 
Dose Titration Period (Study APD811-003 Placebo-treated Subjects) 
......... 38
 
5.6.1.2 
Treatment Period 
............................................................................................ 40
 
5.6.2 
Extended-release Tablets.................................................................................... 41
 
5.6.2.1 
Formulation Switch and Dose Titration Period 
............................................. 41
 
5.6.2.2 
Treatment Period 
............................................................................................ 42
 
5.7 METHOD OF ASSIGNING SUBJECTS TO TREATMENT GROUPS ............. 42
 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 12 
5.8 RANDOMIZATION AND BLINDING ................................................................. 42
 
6 STUDY PROCEDURES 
.............................................................................................. 42
 
6.1 INFORMED CONSENT......................................................................................... 43
 
6.2 MEDICAL AND SOCIAL HISTORY 
................................................................... 43
 
6.3 PHYSICAL EXAMINATION 
................................................................................ 43
 
6.4 VITAL SIGNS 
......................................................................................................... 43
 
6.5 ELECTROCARDIOGRAPHY .............................................................................. 44
 
6.5.1 
ECG Equipment 
................................................................................................. 44
 
6.5.2 
ECG Acquisition 
................................................................................................. 44
 
6.5.3 
ECG Assessment 
................................................................................................. 45
 
6.6 6-MINUTE WALK TEST....................................................................................... 45
 
6.7 WHO/NYHA FUNCTIONAL CLASS ASSESSMENT 
......................................... 46
 
6.8 RIGHT HEART CATHETERIZATION 
............................................................... 46
 
6.9 ASSESSMENT OF CLINICAL WORSENING 
.................................................... 47
 
6.10 CLINICAL LABORATORY TESTS 
..................................................................... 47
 
6.10.1 Laboratory Parameters 
...................................................................................... 48
 
6.10.2 Urinalysis 
............................................................................................................ 49
 
6.10.3 Sample Collection, Storage, and Shipping 
......................................................... 49
 
6.11 BNP/NT-proBNP 
..................................................................................................... 49
 
6.12 ADVERSE EVENTS ASSESSMENTS 
.................................................................. 50
 
6.12.1 Adverse Event Reporting 
................................................................................... 50
 
6.12.2 Serious Adverse Events and Expedited Reporting of Adverse Events 
............. 51
 
6.12.3 Pregnancy 
........................................................................................................... 52
 
6.12.4 Assessment of Adverse Event Severity .............................................................. 53
 
6.12.5 Assessment of Adverse Event Relationship to Study Drug 
............................... 53
 
6.12.6 Assessment of Adverse Event Outcome 
............................................................. 54
 
6.12.7 Action Taken for Adverse Event 
........................................................................ 54
 
6.12.7.1 Action Taken for Study Drug 
......................................................................... 54
 
6.12.8 Collection of Extra Laboratory Samples/Investigations 
................................... 54
 
6.12.9 Follow-up of Adverse Events Present at Last Scheduled Study Visit 
............... 55
 
6.13 CONCOMITANT MEDICATION ASSESSMENTS ............................................ 55
 
6.14 REMOVAL OF SUBJECTS FROM THE STUDY OR STUDY DRUG 
.............. 56
 
6.14.1 Handling of Withdrawals 
................................................................................... 56
 
6.15 ALLOWABLE VISIT AND PROCEDURE WINDOWS ..................................... 57
 
7 STUDY ACTIVITIES ................................................................................................. 57
 
7.1 SCREENING VISIT 
............................................................................................... 57
 
7.2 STUDY PROCEDURES 
......................................................................................... 58
 
7.2.1 
Baseline Study Procedures – All Subjects ......................................................... 58
 
7.2.1.1 
Pre-baseline Procedures.................................................................................. 58
 
7.2.1.2 
Baseline Procedures 
........................................................................................ 58
 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 13 
7.2.2 
Study Procedures – for Immediate-release Dose Titration Period (Study 
APD811-003 Placebo Subjects) 
.......................................................................... 59
 
7.2.2.1 
Pre-dose Procedures for Dose Titration Period Visits (Study APD811-
003 Placebo Subjects) 
...................................................................................... 59
 
7.2.2.2 
Post-dose Procedures for Dose Titration Period Visits (Study APD811-
003 Placebo Subjects) 
...................................................................................... 60
 
7.2.3 
Study Procedures for the Treatment Period – All Subjects (For Both 
Immediate-release and Extended-release Formulations) 
.................................. 60
 
7.2.3.1 
Study Procedures M1-M3 (Study APD811-003: Placebo-treated 
Subjects) Q3 Months (Study APD811-003: Placebo- and Ralinepag-
treated Subjects; Subjects who Switched to the XR Formulation) 
............... 60
 
7.2.3.2 
Study Procedures - Year 1 or Year 2 ............................................................. 60
 
7.2.3.3 
Switch to XR Ralinepag and Dose Titration 
.................................................. 60
 
7.2.4 
End of Study Visit – All Subjects 
....................................................................... 61
 
7.2.5 
28-day Follow-up – All Subjects ........................................................................ 61
 
8 DATA MANAGEMENT 
............................................................................................. 61
 
8.1 DATA COLLECTION............................................................................................ 61
 
8.2 DATA CODING 
...................................................................................................... 62
 
8.2.1 
Adverse Events 
................................................................................................... 62
 
8.2.2 
Concomitant Medications .................................................................................. 62
 
9 PLANNED STATISTICAL METHODS 
.................................................................... 62
 
9.1 ANALYSIS POPULATIONS 
................................................................................. 62
 
9.2 STATISTICAL METHODS 
................................................................................... 63
 
9.2.1 
Safety Analysis 
.................................................................................................... 63
 
9.2.1.1 
Demographics and Baseline Characteristics 
.................................................. 63
 
9.2.1.2 
Adverse Events 
................................................................................................ 63
 
9.2.1.3 
Physical Examinations 
.................................................................................... 63
 
9.2.1.4 
Vital Signs........................................................................................................ 64
 
9.2.1.5 
Clinical Laboratory Values............................................................................. 64
 
9.2.1.6 
Safety ECGs 
.................................................................................................... 64
 
9.2.2 
Statistical Analyses of Efficacy Measurements ................................................. 64
 
10 REGULATORY REQUIREMENTS 
.......................................................................... 65
 
10.1 PRE-STUDY DOCUMENTATION 
....................................................................... 65
 
10.2 INVESTIGATOR OBLIGATIONS 
....................................................................... 65
 
10.3 SUBJECT CONFIDENTIALITY .......................................................................... 65
 
10.4 INFORMED CONSENT......................................................................................... 66
 
10.5 INSTITUTIONAL REVIEW BOARD 
................................................................... 66
 
11 PROTOCOL MANAGEMENT AND ADMINISTRATIVE 
CONSIDERATIONS 
................................................................................................... 66
 
11.1 STUDY DOCUMENTATION 
................................................................................ 66
 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 14 
11.2 PROTOCOL INTERPRETATION AND COMPLIANCE .................................. 67
 
11.3 STUDY MONITORING 
......................................................................................... 67
 
12 REFERENCE LIST ..................................................................................................... 68
 
 
List of Appendices 
Appendix 1 Guidelines for 6-Minute Walk Test............................................................... 70
 
Appendix 2 Functional Classification of Pulmonary Hypertension Modified After The 
New York Heart Association Functional Classification According to the 
WHO 1998 
................................................................................................... 75
 
 
Table of In-Text Tables 
Table 1
 
Schedule of Procedures and Visits: Study APD811-003 Subjects Treated 
with Ralinepag Entering Study APD811-007 
................................................ 31
 
Table 2
 
Schedule of Procedures and Visits: Study APD811-003 Subjects treated 
with Placebo entering Study APD811-007 
.................................................... 33
 
Table 3
 
Possible Dosing Regimen during 9-Week Dose Titration Period 
................... 40
 
Table 4
 
Possible Dosing Regimen during the Treatment Period................................. 41
 
Table 5 
Dose Switching Guidance from Immediate-release to Extended-release 
Ralinepag 
..................................................................................................... 41
 
 
Table of In-Text Figures 
Figure 1 
Evidence-based Treatment Algorithm for PAH 
............................................. 20
 
 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 15 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
6MWD 
6-Minute Walk distance 
6MWT 
6-Minute Walk Test 
ADL 
Activities of Daily Living 
ADR 
Adverse drug reaction 
AE 
Adverse event 
AUC 
Area under the curve 
BP 
Blood pressure 
BID 
Twice daily 
BNP 
Brain natriuretic peptide 
Cmax 
Maximal drug concentration 
CRF 
Case Report Form 
CRO 
Contract Research Organization 
EC50 
Median effective concentration 
ECG 
Electrocardiogram 
ERA 
Endothelin receptor antagonist 
FC 
Functional Class 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
GLP 
Good Laboratory Practice 
hCG 
Human chorionic gonadotropin 
hERG 
Human Ether-a-go-go-related gene 
IC50 
Half maximal inhibitory concentration 
ICF 
Informed Consent Form 
ICH 
International Council for Harmonisation 
IEC 
Independent Ethics Committee 
IP 
Prostacyclin receptor 
IR 
Immediate-release 
IRB 
Institutional Review Board 
IV 
Intravenous(ly) 
MedDRA 
Medical Dictionary for Regulatory Activities 
MTD 
Maximum tolerated dose 
NOAEL 
No-observed-adverse-effect level 
NT-proBNP 
N-Terminal pro-brain natriuretic peptide 
NYHA 
New York Heart Association 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 16 
PAH 
Pulmonary arterial hypertension 
PAP 
Pulmonary artery pressure 
PCWP 
Pulmonary capillary wedge pressure 
PDE5-I 
Phosphodiesterase type 5 inhibitor 
PGI2 
Prostaglandin I
2 
PH 
Pulmonary hypertension 
PK  
Pharmacokinetic(s) 
PVR 
Pulmonary vascular resistance 
Q3 
Every 3 
QD 
Once daily 
QTcB 
QT interval corrected for Bazett’s formula 
QTcF 
QT interval corrected for Fridericia’s formula 
RHC 
Right heart catheterization 
RR 
Respiratory rate 
SAE 
Serious adverse event 
SC 
Subcutaneous(ly) 
sGC 
Soluble guanylate cyclase 
SOP 
Standard Operating Procedure 
SVR 
Systemic vascular resistance 
TEAE 
Treatment-emergent adverse event 
t
max 
Time of maximum plasma concentration 
WHO 
World Health Organization 
XR 
Extended-release 
 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 17 
1 
INTRODUCTION 
Ralinepag is an orally available potent and selective, nonprostanoid, prostaglandin I2 (PGI
2, 
prostacyclin, IP) receptor agonist.  The IP receptor is a rhodopsin-like transmembrane 
spanning G protein-coupled receptor which is expressed on platelets and on the smooth 
muscle cells of several tissues, including the lung, heart, aorta, liver, kidneys, and blood 
vessels.  Activation of the IP receptor results in vasodilation and inhibits platelet aggregation.1 
Ralinepag is being developed to treat World Health Organization (WHO) Group 1 pulmonary 
hypertension, designated as pulmonary arterial hypertension (PAH).  Elevated pulmonary 
artery pressure (PAP) in PAH is thought to result from primary pathological alterations in 
pulmonary arterioles.  PAH is a rare, progressive disease characterized by elevated pulmonary 
vascular resistance (PVR) that leads to right ventricular failure and ultimately premature 
death.  Prior to the development of effective therapies for PAH, the median survival of 
subjects with idiopathic PAH was approximately 2.8 years.
2  Though the median survival of a 
more recent, large, US cohort has improved to approximately 7 years3 from time of diagnosis, 
PAH remains a severe, often fatal condition.  Pulmonary arterial hypertension is associated 
with alterations in prostacyclin and thromboxane A
2 activity, the balance of which plays a 
major role in maintaining normal pulmonary vascular tone.2,4  Prostacyclin, released by 
endothelial cells, promotes vasodilation and inhibits platelet aggregation by binding to G 
protein-coupled receptors on nearby vascular smooth muscle cells and platelets.  Prostacyclin 
also has antiproliferative effects on vascular smooth muscle.  In direct opposition, 
thromboxane A
2 promotes vasoconstriction and platelet aggregation.  An imbalance in this 
homeostasis towards vasoconstriction, in situ thrombosis, and remodeling of the small 
pulmonary arteries results in pulmonary hypertension (PH).
4,5 
Studies indicate that subjects with PH have decreased levels of prostacyclin.
4,6  Epoprostenol, 
an intravenous (IV) prostanoid which binds to the IP receptor, is the only therapy to 
demonstrate improved survival compared to conventional therapy, supporting utility of the IP 
receptor as a target for PAH therapy.7  Epoprostenol requires continuous infusion through a 
portable pump, is unstable at room temperature, and is associated with catheter related 
infections and thrombosis.  Subsequent forms of prostanoids have been developed to address 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 18 
some of the limitations of epoprostenol and have demonstrated efficacy through improved 
exercise capacity and/or delay in clinical worsening.  
The clinical definition of PH requires confirmation by right heart catheterization (RHC) 
demonstrating a mean PAP >25 mmHg.  The diagnosis of PAH requires a normal (≤15 
mmHg) pulmonary capillary wedge pressure (PCWP) and an increase in PVR in addition to 
an elevated mean PAP.  The latest clinical classification by the Sixth World Symposium on 
Pulmonary Hypertension divides PH into 5 categories based on similarities in clinical 
presentation, pathogenesis, and response to treatments.8  PAH is the first category (Group 1) 
and is further divided into subgroups reflecting associated conditions.  All subgroups in 
Group 1 PH share similar clinical characteristics and virtually identical histopathology in the 
pulmonary arteriolar circulation.  
There is a wide variation in the reported prevalence of PAH; 15 to 50 cases/million with a 
higher female preponderance (~3:1).9,10,11  The range in reported prevalence is likely due to 
the difficulty in diagnosing early PAH.  Patients are usually asymptomatic in the earliest 
stages of the disease, and presenting symptoms, which include exertional dyspnea, fatigue, 
peripheral edema, and syncope, can be indistinguishable from other cardiorespiratory 
diseases.  The majority of patients are not diagnosed until they have developed symptoms of 
WHO (modification of the New York Heart Association [NYHA] classification for PH) 
Functional Class (FC) III. 
The current evidence-based recommended treatment algorithm emerged from the Fifth World 
Symposium on Pulmonary Hypertension12 and is summarized in Figure 1.  The majority of 
patients who undergo acute vasoreactivity testing are classified as nonresponders and are 
therefore candidates for treatment with an endothelin receptor antagonist (ERA), a 
phosphodiesterase type 5 inhibitor (PDE5-I) or a prostacyclin receptor agonist, depending 
upon the severity of symptoms.  Patients with inadequate response to initial medical therapy 
may progress to combination drug therapy or ultimately to surgical procedures that could 
include lung transplantation. 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 19 
Due to availability of oral dosage forms, almost all patients initiate therapy with an ERA or a 
PDE5-I.  The report from the Fifth World Symposium on Pulmonary Hypertension points out 
that the clinical role of aggressive early therapy with prostacyclin receptor agonists remains 
unknown since in randomized controlled studies, the available agents were evaluated 
primarily in subjects with more advanced disease.  Multiple attempts at developing an IP 
receptor agonist for oral administration  have been limited by molecules with unfavorable 
pharmacokinetic (PK) properties.  Thus, there is a need for additional effective oral agents 
targeting the prostacyclin pathway. 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 20 
Figure 1 
Evidence-based Treatment Algorithm for PAH 
 
Abbreviations: APAH, associated pulmonary arterial hypertension; BAS, balloon atrial septostomy; CCB, calcium 
channel blockers; ERA, endothelin receptor antagonist; FC, Functional Class; IPAH, idiopathic pulmonary arterial 
hypertension; IV, intravenous; PAH, pulmonary arterial hypertension; PDE5-I, phosphodiesterase type-5 inhibitor; 
SC, subcutaneous; sGC, soluble guanylate cyclase; WHO, World Health Organization 
Source: Fifth World Symposium on Pulmonary Hypertension12 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 21 
1.1 BACKGROUND INFORMATION 
1.1.1 
Rationale for Proposed Clinical Study 
Despite recent advancements in treatment options, PAH remains a fatal disease with 
approximately 15% mortality within 1 year
15 and a 3-year survival rate between 35% to 75% 
depending on PAH etiology and co-morbid conditions.4,15 There is a significant need for 
alternative treatments for this disease.  Ralinepag, an oral nonprostanoid IP receptor agonist, 
could be an effective and convenient treatment option. 
Ralinepag has been characterized in both single and multiple dose studies in a healthy 
volunteer population.  The safety profile suggests that dose-related pharmacology at the IP 
receptor is occurring within the dose range of 10 to 20 mcg, with adverse effects consistent 
with those reported for IP receptor agonists.  The pathophysiology of PAH may be associated 
with changes in prostacyclin receptors within the pulmonary vascular circulation, and leads to 
differing responses than in healthy volunteers.  This study is being undertaken to evaluate the 
long-term safety and tolerability of ralinepag in subjects with PAH who have completed the 
Phase 2 study, APD811-003, or subjects who were assigned to placebo and were discontinued 
for clinical worsening. 
1.1.2 
Summary of Nonclinical Data 
 
 
 
 
 
 
 
 
 
  


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
1.1.3 
Summary of Clinical Data 
The starting dose of 100 mcg for the first-in-human Study APD811-001 was determined in 
accordance with Food and Drug Administration (FDA) Guidance for Industry, Estimating the 
Maximum Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers 
(2005), and was based on the monkey NOAEL of 100 mcg/kg/day, using a safety factor of 20, 
and assuming a 60-kg human subject. 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 23 
In Study APD811-001, up to 9 single ascending dose cohorts of 8 subjects each (6 active, 
2 placebo) were planned.  The administration of single doses of 30, 50, and 100 mcg were 
generally tolerated in healthy male and female subjects.  The administration of a single dose 
of 200 mcg ralinepag was not well tolerated by subjects and resulted in discontinuation of 
further dose escalation in the study due to nausea and vomiting of severe intensity.  The 
maximum tolerated dose in this clinical study was therefore 100 mcg.  The adverse events 
(AEs) most commonly experienced included headache, vomiting, nausea, and jaw pain. 
No consistent effects were seen on blood pressure (BP), but pulse rate appeared to increase 
more in ralinepag subjects than placebo subjects (delta ~10 bpm) at the 3 highest doses.  
Consequently, uncorrected QT interval decreased, but rate corrected QT interval for 
Fridericia’s formula (QTcF) was increased from baseline at time of maximum plasma 
concentration (t
max) in nondose responsive fashion, by means and medians ranging from 3 to 9 
msec at the 2 highest doses.  An effect on QT interval is not supported by preclinical findings 
(human ether-à-go-go-related gene [hERG] concentration that inhibits 50% [IC50] >20 µM, 
and no effect on QTc in a primate cardiovascular study at 3 to 4 times the C
max achieved in the 
Phase 1 study).  No dose response on QT interval was seen, and the significance of the 
findings in this limited study is unclear. 
A subsequent multiple ascending dose study was conducted in healthy volunteers (Study 
APD811-002).  The safety and tolerability of 2 different dosing regimens was evaluated: a 
once-daily regimen in Cohorts 1 and 2 (run concurrently) began at an initial dose of 50 mcg 
and was escalated as tolerated to doses of 100, 200, 300, and 400 mcg at 5-day intervals, and 
a twice-daily regimen in Cohort 3 began at an initial dose of 10 mcg twice daily (BID) and 
was escalated as tolerated to doses of 20, 30, 40, 50, and 70 mcg BID at 5-day intervals.  In 
Cohorts 1 and 2, a total of 30 subjects were dosed, with 20 subjects receiving ralinepag and 10 
subjects receiving placebo.  In Cohort 3, a total of 25 subjects were dosed, with 20 subjects 
receiving ralinepag and 5 subjects receiving placebo. 
Overall tolerability for both dosing regimens was similar; when comparing the total daily dose 
taken by subjects for at least 3 consecutive days, 40% of subjects tolerated a total daily dose 
of 100 mcg or higher with either QD or BID regimens.  The specific AEs observed were 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 24 
similar for each of the dosing regimens and included headache, nausea, vomiting, jaw pain, 
and flushing; nausea and vomiting occurred more frequently with the once-daily dosing 
regimen.  The AEs observed in the study were similar to the AE profile seen with other IP 
receptor agonists.  As this study was designed to titrate to individual tolerability, it was not 
surprising that the majority of AEs for subjects on active drug were moderate in intensity and 
were considered by the Investigator to be probably related to study drug. 
One serious adverse event (SAE), transient atrial fibrillation, occurred in a single subject 
during the first portion of the study after receiving 5 days of 50 mcg QD.  Study drug was 
discontinued.  The subject was admitted overnight to a hospital, treated with metoprolol and 
subcutaneous (SC) heparin and spontaneously converted to sinus rhythm.  No further episodes 
of atrial fibrillation occurred after several additional days of monitoring, or after discharge.  
The Investigator considered the event to be of moderate intensity and possibly related to study 
drug.  The subject was subsequently evaluated in a cardiology clinic, with no etiology 
identified for the resolved bout of atrial fibrillation.  
For all cohorts, the majority of AEs experienced by subjects in the active treatment group 
were those that coded to the System Organ Classes Nervous System Disorders, 
Gastrointestinal Disorders, and Musculoskeletal and Connective Tissue Disorders (Medical 
Dictionary for Regulatory Activities [MedDRA] v. 13.1).  Headache, nausea, pain in jaw, and 
vomiting were the most commonly reported preferred terms.  There were no deaths reported 
in the study. 
Ralinepag appears to be associated with a vasodilatory effect at lower doses, and reflex 
tachycardia at higher doses.  These hemodynamic effects were not limiting for dose 
escalation.  These observations are consistent with the expected pharmacology of ralinepag 
and are also consistent with observations for other IP receptor agonists. 
Intensive electrocardiogram (ECG) monitoring was undertaken in this study to better 
understand possible effects of ralinepag on QT interval and to evaluate risk for QT effects.  
Ralinepag in the dose range administered in this study is not likely to be associated with QT 
prolongation.  Mean ∆∆QTcF was below 5 msec for plasma levels up to the highest levels 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 25 
achieved, approximately 10 ng/mL, with an upper bound of the 90% confidence interval 
below 10 msec, the threshold of regulatory concern.  
Results of the PK measurements of ralinepag demonstrate that the median time of maximum 
plasma concentration (tmax) for ralinepag was similar between doses and occurred between 1.0 
to 1.5 hours post-dose.  The half-life of ralinepag was consistent across doses and was 
between 20.5 to 26.4 hours.  The apparent oral clearance was low compared to hepatic blood 
flow.  The apparent volume of distribution was moderate (~2-fold that of total body water).  
Clearance and volume of distribution were dose independent.   
Study APD811-004 was conducted as an open-label, randomized, single-dose, 2-treatment, 
crossover study to assess the PK properties of ralinepag at a dose of 30 mcg in the fed and 
fasted states.  The tmax in the fed state was delayed compared to the fasted state (from 1 to 
~4 h), the C
max reduced (estimated geometric mean ratio ~0.6), and the AUC largely 
maintained (estimated geometric mean ratio ~0.8).  These results support dosing of ralinepag 
with food. 
Study APD811-003 was a randomized, double-blind, parallel-group, placebo-controlled, 
Phase 2 study of ralinepag in subjects with PAH.  In this 61-subject study, the primary 
efficacy analysis demonstrated a statistically significant absolute change from Baseline in 
PVR compared to placebo.  Ralinepag also demonstrated numerical improvement in 6-Minute 
Walk Distance (6MWD).  Ralinepag improved median PVR by 163.9 dyn.s.cm
-5 from 
baseline compared to a 0.7 dyn.s.cm
-5 worsening from baseline in the placebo arm (p=0.02).  
Subjects treated with ralinepag had a 29.8% reduction in PVR compared to the placebo arm 
(p=0.03) and a 20.1% reduction in PVR compared to baseline.  Additionally, AEs observed in 
the study were consistent with other prostacyclin treatments for the management of PAH, 
with headache, nausea, diarrhea, jaw pain, and flushing being the most commonly reported 
AEs.  Additional information is be presented in the Investigator’s Brochure. 
In Study APD811-011, an extended-release (XR) tablet formulation of ralinepag was 
evaluated in a dose escalation paradigm over approximately 4 weeks (with daily dosing 
starting at 60 mcg and slowly up-titrating, depending upon individual subject tolerability, by 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 26 
additional 60 mcg dose increments every 5 days up to 30 mcg) in healthy subjects in both the 
fasted and fed states. 
The data from this study showed that ralinepag peak and total plasma exposure for the XR 
tablet were dose dependent (appearing only slightly higher than dose proportional) and did not 
appreciably vary when taken with or without food.  Lastly, the XR tablet shows a higher 
plasma concentration at 24 h compared to the immediate-release (IR) capsule, indicating an 
improved plasma PK performance over the IR capsule with respect to once-daily dosing in 
terms of extending exposure and minimizing peak-to-trough fluctuation. 
Overall, there were no deaths or SAEs, and all AEs were mild or moderate with the exception 
of 1 Grade 3 adverse drug reaction (ADR).  In both the fasted and fed states, the majority of 
subjects experienced at least 1 AE, most of which were ADRs, and the number and 
percentage of AEs and ADRs were comparable.  The majority of AEs were transient in nature 
and had resolved by the end of the study.  The profile of AEs from both fasted and fed 
subjects were consistent with the reference safety information for ralinepag and other 
prostacyclin receptor agonists, with notable exceptions of the AEs of Grade 3 increased 
transaminases and Grade 1 ventricular extrasystoles. 
1.2 ETHICS AND REGULATORY CONSIDERATIONS 
The study will be conducted in compliance with the ethical principles that have their origin in 
the Declaration of Helsinki on biomedical research involving human volunteers 
(2013 Version), International Council for Harmonisation (ICH) of Technical Requirements 
for Pharmaceuticals for Human Use Guidelines for Good Clinical Practice (GCP), the study 
protocol, and where applicable, Sponsor and/or Contract Research Organization (CRO) 
Standard Operating Procedures (SOPs).  The protocol and informed consent will be submitted 
for consideration by the appropriate Independent Review Board (IRB)/Independent Ethics 
Committee (IEC) and written approval from the Chair or designated deputy of the IRB/IEC is 
required before clinical activities of the study can commence. 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 27 
The IRB/IEC must be notified promptly by the Investigator of the following: 
• Deviations from, or changes in, the protocol to eliminate immediate hazards to the 
study subjects 
• Changes increasing the risk to subjects and/or significantly affecting the conduct of 
the study 
• All AEs that meet the definition of an SAE 
• New information that may affect adversely the safety of the subjects or the conduct of 
the study 
Any changes to the protocol will be made by means of a formal written protocol amendment.  
All amendments will require IRB/IEC approval before implementation, except when changes 
to the protocol are required immediately to eliminate hazards to the subjects. 
2 
STUDY OBJECTIVES 
2.1 PRIMARY OBJECTIVE 
To evaluate the long-term safety and tolerability of ralinepag in subjects with WHO Group 1 
PAH who have completed Study APD811-003. 
2.2 SECONDARY OBJECTIVES 
• To evaluate the effect of ralinepag in subjects with WHO Group 1 PAH who 
completed Study APD811-003, as determined by the incidence of clinical worsening. 
• To evaluate changes from baseline in the following efficacy endpoints:  
• 6MWD 
• WHO/NYHA FC 
• Hemodynamics 
3 
INVESTIGATIONAL PLAN 
3.1 OVERALL STUDY DESIGN AND PLAN 
This is a Phase 2, multicenter, open-label, extension study to determine the long-term safety 
and tolerability of ralinepag in subjects with WHO Group 1 PAH who have completed the 
Phase 2 study, APD811-003, or who were assigned to placebo and were discontinued for 
clinical worsening.  Subjects must also meet eligibility criteria for participation in this long-
term extension study.  The Day 1 (Baseline) visit in Study APD811-007 will coincide with the 
Week 25 Visit in Study APD811-003.  For this reason, subjects should be consented to Study 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 28 
APD811-007 prior to the Week 25 procedures being performed for Study APD811-003.  
Baseline/Day 1 evaluations will include medical history update, assessment of disease state, 
and determination of eligibility for each potential subject.   
All subjects enrolled in Study APD811-007 will receive open-label treatment with ralinepag.  
The starting dose and titration schedule will be individually determined in accordance with 
the starting dose and titration schedule optimized from Study APD811-003.  Adjustments in 
the dose and titration schedule may be made according to subject tolerability.  After the 
completion of Study APD811-003, ongoing safety review of subject data will be conducted 
by the Sponsor to monitor for drug safety. 
After an individual subject completes Study APD811-003 and that subject’s database is 
locked, subject unblinding will occur.  Subjects who were on active treatment (ralinepag) in 
Study APD811-003 will remain on current dose and have onsite clinical assessments 
performed every 3 months until the subject is discontinued from the study (see Table 1).  
Subjects in the placebo treatment group of Study APD811-003 will undergo a Dose Titration 
Period until a stable maximum tolerated dose (MTD) is reached (up to 9 weeks); this will be 
followed by a Treatment Period in which monthly onsite clinic assessments will be performed 
for the first 3 months and then every 3 months until the subject is discontinued from the study 
or the study is terminated (see Table 2).  
Subjects will continue to have visits to the clinic every 3 months indefinitely to collect data as 
specified in Table 1 and Table 2 until marketing approval of ralinepag is granted or until the 
Sponsor discontinues the study.  
During the conduct of the study, subjects will switch from the IR formulation of ralinepag (as 
studied in ADP811-003) to an XR formulation that will be used in Phase 3 studies.  
For both IR and XR formulations, dose reductions may be made at any time for 
safety/tolerability reasons.  Incremental dose increases will also be allowed during the 
Treatment Period (Table 1 and Table 2) at the discretion of the Investigator (as clinically 
indicated) and according to the stepwise titration scheme outlined in Table 4. 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 29 
Subjects will be assessed for clinical worsening during each clinic visit.  If clinical worsening 
is confirmed, the Investigator may opt to either continue treatment with ralinepag at the 
current dose, increase the dose of ralinepag, interrupt treatment, or discontinue the subject at 
his/her discretion.  Addition/dose increases/substitutions of 1 drug within the ERA class and 1 
within the PDE5-I/soluble guanylate cyclase (sGC) stimulator class are also permissible. 
In addition, all subjects will be contacted at the time of Study APD811-007 closure to assess 
vital (mortality) status.  The vital status follow-up contact of subjects will depend on local 
regulations or specific agreement with the subject and Investigator. 
Upon termination of the study, subjects will complete an End of Study Visit.  A 28-day 
Follow-up Visit will be conducted to ensure appropriate subject safety.  This visit may be 
conducted by telephone or in person based upon the Investigator’s discretion.  Subjects who 
remain on ralinepag at study termination and meet all eligibility criteria are eligible to roll into 
the open-label extension study (ROR-PH-303). 
Concomitant Medications: 
Subjects are permitted oral disease-specific PAH therapy consisting of an ERA and/or a 
PDE5-I or sGC stimulator, but not both.  The on-study addition/substitution of an ERA, 
PDE5-I/sGC stimulator, if on a single such agent at Baseline, or dosage increase for such 
agents is permitted.  In addition to ralinepag, subjects can be prescribed no more than 1 agent 
from the ERA class and 1 from the PDE5-I/sGC stimulator class at any 1 time.  Substitution 
and dose adjustment within each of these classes is permitted.  Subjects should be evaluated 
for the presence of clinical worsening if additional therapy or dose adjustments/substitutions 
of current therapies are required. 
In addition, the following therapies, which may affect PAH, are permitted and may be 
adjusted in dose as needed:   
• Vasodilators (including calcium channel blockers) 
• Digoxin 
• Spironolactone 
• L-Arginine supplementation 


United Therapeutics Corp. 
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 30 
Diuretics may be dosed as clinically indicated throughout the study. 
Subjects who require treatment with a prostacyclin/prostacyclin analogue (IV, SC, oral, or 
inhaled), except for acute vasodilator testing during cardiac catheterization, will be 
discontinued from the study.  
3.2 RATIONALE FOR STUDY DESIGN 
This study is designed to evaluate the long-term safety and tolerability of ralinepag in subjects 
with PAH. 
Inclusion of a placebo arm in Study APD811-003 and the requirement to maintain the blind in 
that study necessitates the re-titration of all subjects entering Study APD811-007.  Thus, the 
dose titration scheme from Study APD811-003 will be employed in this study for subjects 
who were previously treated with placebo in Study APD811-003. 
Optimal dosing of IP receptor agonists in PAH subjects requires dose titration on an 
individualized basis; furthermore, tolerability may improve with continued exposure.
15  It is 
anticipated that the starting dose of 10 mcg BID will be tolerated by most, if not all, subjects.  
Data from the previous Phase 1 dose titration study suggests that there are individual 
differences in tolerability of ralinepag in healthy volunteers, consistent with findings from 
other studies of prostacyclin receptor agonists in PAH subjects.  


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 31 
Table 1 
Schedule of Procedures and Visits: Study APD811-003 Subjects Treated with Ralinepag Entering Study APD811-
007 
Evaluationa 
Baselineb 
(APD811-003 
Week 25 Visit) 
Treatment Period 
End of Study 
(EOS) 
28-Day 
Follow-Upc 
Q3 Months 
1 or 2 Years 
±5 days 
±3 months 
±3 days 
±3 days 
Informed consent 
X 
 
 
 
 
Medical history 
X 
 
 
 
 
Physical exam 
X 
 
 
X 
 
ECG (12-lead)
d 
X 
X 
 
X 
 
Clinical laboratory testse 
X 
X 
 
X 
 
Pregnancy testf 
X 
X 
 
X 
 
Vital signsg 
X 
X 
 
X 
 
Study drug administration 
Xh 
X 
 
 
 
6MWT 
X 
X 
 
X 
 
BNP/NT-proBNPk 
X 
X 
 
 
 
Assessment of clinical worsening 
X 
X 
 
X 
X 
WHO/NYHA FC assessmenti 
X 
X 
 
X 
X 
RHCl 
 
 
X 
 
 
Dose escalation/de-escalation assessment 
 
Xj 
 
 
 
Adverse event monitoring 
X 
X 
 
X 
X 
Concomitant medication monitoring 
X 
X 
 
X 
X 
Abbreviations: 6MWT, 6-Minute Walk Test; BNP, brain natriuretic peptide; ECG, electrocardiogram; FC, Functional Class; hCG, human chorionic gonadotropin; NT-
proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; Q3, every 3; QTcB, QT interval corrected for Bazett’s formula; QTcF, QT 
interval corrected for Fridericia’s formula; RHC, right heart catheterization; RR, respiration rate; WHO, World Health Organization 
a Reference to pre-dose and post-dose activities in this schedule apply to the morning dose of study drug.  Study drug should be taken with food. 
b  The Week 25 (Day 175) Visit from Study APD811-003 will serve as the Baseline/Day 1 Visit for Study APD811-007. 
c  This visit may be conducted by telephone or in person based upon the Investigator’s discretion. 
d  Safety ECGs should be completed pre-dose.  After the last subject enrolled in Study APD811-007 completes approximately 6 months of treatment and a cumulative all-
subject data analysis is performed, as outlined in Section 9 (Planned Statistical Methods), ECGs will subsequently be conducted locally at the discretion of the 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 32 
Investigator (as clinically indicated) during the Q3 monthly visits.  The ECG will be performed at the End of Study Visit.  Locally collected ECG values for RR, PR, 
QRS, QT, QTc, QTcB, and QTcF will be collected in the Sponsor’s clinical database. 
e  Clinical laboratory tests will include hematology, serum chemistry, coagulation, and urinalysis.  Clinical laboratory tests will be completed pre-dose.  After the last subject 
enrolled in Study APD811-007 completes approximately 6 months of treatment and a cumulative all-subject data analysis is performed, as outlined in Section 9, clinical 
laboratory tests will subsequently be conducted locally at the discretion of the Investigator (as clinically indicated) during the Q3 monthly visits.  A complete clinical 
laboratory test will be conducted locally at the End of Study Visit.  Locally collected laboratory values that are abnormal and clinically significant will be collected in the 
Sponsor’s clinical database along with the reference ranges. 
f  Serum hCG pregnancy tests will be completed pre-dose at each visit during the Treatment Period.  After the last subject enrolled in Study APD811-007 completes 
approximately 6 months of treatment and a cumulative all-subject data analysis is performed, as outlined in Section 9, pregnancy testing (either serum or urine) will 
subsequently be conducted locally during each Q3 monthly and the End of Study Visit.  Locally collected positive values for hCG will be collected in the Sponsor’s 
clinical database along with the reference range. 
g  Vital sign measurements (blood pressure, heart rate, respirations, and body temperature taken in supine position after 5 minutes of rest) will be taken pre-dose. 
h Subjects treated with ralinepag in Study APD811-003 study will
 continue on current
 dose. 
i WHO/NYHA Functional Class will be assessed pre-dose at all visits. 
j  An assessment for further dose escalation or de-escalation will be conducted during the Q3 months. 
k After the last subject enrolled in Study APD811-007 completes approximately 6 months of treatment and a cumulative all-subject data analysis is performed, as outlined in 
Section 9 (Planned Statistical Methods), pro-BNP and NT-proBNP testing will subsequently be conducted locally at the discretion of the Investigator (as clinically 
indicated) during the Q3 monthly visits.  Locally collected values will be entered into the Sponsor’s clinical database along with the reference ranges. 
l At 1 year (±3 months) after the subject enrolls into Study APD811-007, an RHC assessment will be conducted.  If the subject has been in Study APD811-007 beyond 1 
year (±3 months) at the time of regulatory/ethics approval of this amendment, an RHC assessment will be conducted at 2 years (±3 months) instead.  If a subject has been 
enrolled in Study APD811-007 more than 2 years at the time of regulatory/ethics approval of Amendment #02, an RHC will be performed at the time of those approvals. 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 33 
Table 2 
Schedule of Procedures and Visits: Study APD811-003 Subjects treated with Placebo entering Study APD811-007 
Evaluationa 
Baselineb  
(APD811-003 
Follow-up 
Visit) 
Dose Titration Period 
Treatment Period 
End of 
Study 
(EOS) 
28-Day 
Follow-
Upc 
9-Week Period 
M1-M3 Q3 Months 1 or 2 Years 
1 2 3 4 5 6 7 8 9 ±3 days ±5 days 
±3 months ±3 days 
±3 days 
Informed consent 
X 
         
 
 
 
 
 
Medical history 
X 
         
 
 
 
 
 
Physical exam 
X 
         
 
 
 
X 
 
ECG (12-lead)
d 
X 
X X X X X X X X X 
X 
X 
 
X 
 
Clinical laboratory testse 
X 
 X   X    X 
X 
X 
 
X 
 
Serum pregnancy testf 
X 
    X     
X 
X 
 
X 
 
Vital signsg 
X 
X X X X X X X X X 
X 
X 
 
X 
 
Study drug administration 
 
X X X X X X X X X 
X 
X 
 
 
 
6MWTh 
X 
         
X 
X 
 
X 
 
BNP/NT-proBNPk 
X 
         
 
X 
 
 
 
WHO/NYHA functional class 
assessment
i 
X 
X X X X X X X X X 
X 
X 
 
X 
X 
Assessment for clinical 
worsening 
X 
X X X X X X X X X 
X 
X 
 
X 
X 
RHCl 
 
         
 
 
X 
 
 
Dose escalation/de-escalation 
assessment 
 
         
 
Xj 
 
 
 
Adverse event monitoring 
X 
X X X X X X X X X 
X 
X 
 
X 
X 
Concomitant medication 
monitoring 
X 
X X X X X X X X X 
X 
X 
 
X 
X 
Abbreviations: 6MWT, 6-Minute Walk Test; BNP, brain natriuretic peptide; ECG, electrocardiogram; hCG, human chorionic gonadotropin; MTD, maximum tolerated dose; 
NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; Q3, every 3; QTcB, QT interval corrected for Bazett’s formula; QTcF, QT 
interval corrected for Fridericia’s formula; RHC, right heart catheterization; RR, respiratory rate; WHO, World Health Organization 
a Reference to pre-dose and post-dose activities in this schedule apply to the morning dose of study drug.  Study drug should be taken with food. 
b  The Week 25 Visit from Study APD811-003 will
 serve as the Baseline/Day 1 Visit for Study APD811-007. 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 34 
c  This visit may be conducted by telephone or in person based upon the Investigator’s discretion.
 
d  Safety ECG measurements to be completed at Baseline and at Weeks 1 to 9, unless the subject reaches a stable MTD and the subject transitions into the Treatment Period; 
ECGs will be completed pre-dose and 2 hours post-dose.  After the last subject enrolled in Study APD811-007 completes approximately 6 months of treatment and a 
cumulative all-subject data analysis is performed, as outlined in Section 9, ECGs will subsequently be conducted locally at the discretion of the Investigator (as clinically 
indicated) during the Q3 monthly visits.  The ECG will be performed at the End of Study Visit.  Locally collected ECG values for RR, PR, QRS, QT, QTc, QTcB, and 
QTcF will be collected in the Sponsor’s clinical database. 
e Clinical laboratory tests will include hematology, serum chemistry, coagulation, and urinalysis.  Clinical laboratory tests will be completed pre-dose.  After the last subject 
enrolled in Study APD811-007 completes approximately 6 months of treatment and a cumulative all-subject data analysis is performed, as outlined in Section 9, clinical 
laboratory tests will subsequently be conducted locally at the discretion of the Investigator (as clinically indicated) during the Q3 monthly visits.  A complete clinical 
laboratory test will be conducted locally at the End of Study Visit.  Locally collected laboratory values that are abnormal and clinically significant will be collected in the 
Sponsor’s clinical database along with the reference ranges. 
f  Serum pregnancy test will be completed pre-dose at each visit during the Treatment Period.  After the last subject enrolled in Study APD811-007 completes approximately 
6 months of treatment and a cumulative all-subject data analysis is performed, as outlined in Section 9 (Planned Statistical Methods), pregnancy testing (either serum or 
urine) will subsequently be conducted locally during each Q3 monthly and the End of Study Visit.  Locally collected positive values for hCG will be collected in the 
Sponsor’s clinical database along with the reference range. 
g  Vital sign measurements (blood pressure, heart rate, respirations, body temperature, and pulse oximetry [SpO
2]), taken in supine position after 5 minutes of rest) will be 
taken at pre-dose on Day 1, and pre-dose on the first day of each dose increase.  On the first day of each dose increase, blood pressure and heart rate will be taken 
approximately every hour for the first 4 hours after study drug administration.  Vital signs will be measured prior to any blood draw that occurs at the same time point.   
h  The 6MWT should be completed pre-dose at approximately the same time of day at each designated visit. 
i WHO/NYHA Functional Class will be assessed pre-dose at all visits. 
j An assessment for further dose escalation or de-escalation will be conducted during the Q3 months. 
k  After the last subject enrolled in Study APD811-007 completes approximately 6 months of treatment and a cumulative all-subject data analysis is performed, as outlined in 
Section 9, pro-BNP and NT-proBNP testing will subsequently be conducted locally at the discretion of the Investigator (as clinically indicated) during the Q3 monthly 
visits.  Locally collected values will be entered into the Sponsor’s clinical database along with the reference ranges. 
l  At 1 year (±3 months) after the subject enrolls into Study APD811-007, an RHC assessment will be conducted.  If the subject has been in Study APD811-007 beyond 1 
year (±3 months) at the time of regulatory/ethics approval of Amendment 2, an RHC assessment will be conducted at 2 years (±3 months) instead.  If a subject has been 
enrolled in Study APD811-007 more than 2 years at the time of regulatory/ethics approval of Amendment 2, an RHC will be performed at the time of those approvals. 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 35 
4 
STUDY POPULATION SELECTION 
4.1 STUDY POPULATION 
The study population will include subjects with WHO Group 1 PAH who have completed 
Study APD811-003 or who were assigned to placebo and discontinued for clinical worsening 
and who are deemed appropriate candidates for participation in this long-term extension 
study. 
All women, regardless of childbearing potential, must have a negative serum human chorionic 
gonadotropin (hCG) pregnancy test at each visit during the Treatment Period and at Week 5 
of the Dose Titration Period, if applicable.  Males and females of childbearing potential must 
use adequate means of contraception and must agree not to participate in a conception process 
(ie, active attempt to become pregnant or impregnation, sperm donation, in vitro fertilization) 
during the study and for 30 days after the last dose of study drug.  Eligible subjects must meet 
all entry criteria prior to being randomized to receive study drug as outlined below.  Any 
deviations from these criteria must be approved by the Sponsor prior to the subject being 
enrolled. 
4.2 INCLUSION CRITERIA 
Each subject must meet the following criteria to be enrolled into the study: 
• Evidence of a personally signed and dated informed consent document 
• Is willing and able to comply with scheduled visits, treatment plan, laboratory tests, 
and other study procedures and is deemed an appropriate candidate for participation in 
this long-term extension study 
• Eligible female subjects will be: 
• Nonpregnant, evidenced by a negative serum hCG pregnancy test at Baseline  
• Nonlactating 
• Surgically sterile or postmenopausal, or agree to continue to use an accepted 
method of birth control for at least 3 months prior to first dose, during, and for at 
least 30 days after last study drug administration 
• Acceptable methods of birth control are: hormonal contraceptives, double 
barrier method, intrauterine device, surgical sterility for at least 6 months prior 
to Screening for tubal ligation performed laparoscopically, surgical sterility for 
at least 6 months prior to Screening by hysterectomy and/or bilateral 
oophorectomy, and/or postmenopausal status (defined as at least 2 years 
without menses).  Intended abstinence is not considered an acceptable method 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 36 
of birth control for this study; subjects must agree to use an acceptable method 
of birth control should they become sexually active during the study or within 
30 days after the last dose of study drug. 
• Eligible male subjects will either be: 
• Surgically sterile (ie, vasectomy) for at least 3 months prior to Screening 
• Agree to use a condom with spermicide when sexually active with a female 
partner who is not using an acceptable method of birth control during the study 
and for 30 days after last study drug administration 
• Eligible male and female subjects must agree not to participate in a conception process 
(ie, active attempt to become pregnant or impregnation, sperm donation, in vitro 
fertilization) during the study and for 30 days after the last dose of study drug 
• Fulfilled all eligibility criteria for Study APD811-003 and completed the study as 
planned 
• Subjects who were assigned to placebo in Study APD811-003 and experienced 
clinical worsening in that study may enroll in Study APD811-007 after he/she has 
completed all end of study procedures per protocol, including RHC, and have had 
their individual Study APD811-003 data locked.  
4.3 EXCLUSION CRITERIA 
Subjects who meet any of the following criteria will be excluded from the study: 
• Subjects who enrolled in Study APD811-003 and were withdrawn from study drug 
treatment due to any AE or SAE, or subjects who did not complete Study 
APD811-003, with the exception made as above for placebo-treated subjects who 
experienced a clinical worsening event. 
• Female subjects who wish to become pregnant 
• Systolic BP <90 mmHg at Baseline 
• Other severe acute or chronic medical or laboratory abnormality that may increase the 
risk associated with study participation or investigational product administration or 
may interfere with the interpretation of study results and, in the judgment of the 
Investigator, would make the subject inappropriate for entry into this study.  
5 
STUDY TREATMENTS 
5.1 TEST ARTICLE 
The Sponsor will provide adequate supplies of ralinepag IR capsules.  Ralinepag will be 
provided as 10, 20, 30, 40, and 100 mcg IR dose strengths, and later will be provided as 50, 
250, and 400 mcg (0.05, 0.25, and 0.4 mg) XR tablet dose strengths. 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 37 
5.2 TREATMENTS ADMINISTERED 
The ralinepag IR formulation initially used in the study is a liquid-filled, size 4, hard-gelatin 
capsule containing ralinepag, polyoxyl 40 hydrogenated castor oil (Kolliphor
® RH40) NF, 
butylated hydroxytoluene NF, and colloidal silicon dioxide NF.  The ralinepag XR 
formulation tablet contains ralinepag, hydroxypropylmethyl cellulose (Methocel K4M 
Premium CF and Methocel K100 Premium LVCR), microcrystalline cellulose (Avicel 
PH102), mannitol (Pearlitol 100 SD), silicon dioxide, and magnesium stearate. 
Ralinepag used for the capsules was manufactured under Current Good Manufacturing 
Practices compliance by the Sponsor (or designee).  The APD811 capsules (IR) or tablets 
(XR) will be manufactured under Current Good Manufacturing Practices compliance by the 
Sponsor (or designee). 
5.3 PACKAGING, LABELING AND STORAGE 
For each IR formulation dosage strength, 74 capsules will be bulk packaged in 40-cc 
high-density polyethylene bottles with a heat induction seal and child-resistant screw caps.  
These bottles should be stored under refrigeration at 2°C (36°F) to 8°C (46°F); the bottles 
should not be frozen. 
XR tablets are packaged in PERLALUX® blisters (polyvinyl chloride 
[PVC]/polythylene/polyvinylidene chloride [PVDC], 250/30/90, and cover foil Alu 20 mcm) 
in a 1×8 configuration and carded in an 8×8 array, 64 tablets per card.  The cards are stored at 
15°C to 30°C (59°F to 86°F). 
5.4 TEST ARTICLE ACCOUNTABILITY 
The Investigator will maintain accurate records of the receipt of all study drug.  In addition, 
accurate records will be kept regarding when and how much study drug is dispensed and used 
by each subject in the study.  Reasons for deviation from the expected dispensing regimen 
must also be recorded.  Study drug will be reconciled by the Sponsor’s monitor or contracted 
designee.  The Investigator agrees to provide sufficient access to study drug as required for 
the reconciliation process to be completed in a timely fashion. 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 38 
5.5 INVESTIGATIONAL PRODUCT RETENTION AT STUDY SITE 
At completion of the study, all study drug will be reconciled by the Sponsor’s monitor or 
contracted designee and then returned to either the Sponsor or a third-party contractor to be 
retained or destroyed according to applicable country regulations and investigative site SOPs.  
Prior to any action being taken with study drug after the study is completed, the Investigator 
will contact the Sponsor (or contracted CRO) for approval of such action. 
5.6 DOSAGE AND ADMINISTRATION 
Investigational product will be dispensed to the subjects under the supervision of the 
Investigator or his/her designee.  Subjects should not crush, break, chew, or dissolve the 
capsules or tablets.  Subjects should wash hands with soap and water after handling drug 
product. 
Capsules or tablets should be taken with food. 
5.6.1 
Immediate-release Capsules 
5.6.1.1 Dose Titration Period (Study APD811-003 Placebo-treated Subjects) 
Subjects who were assigned to placebo treatment in Study APD811-003 will undergo a Dose 
Titration Period of up to 9 weeks.  All subjects will be on active treatment (ralinepag) in the 
open-label study, APD811-007. 
The dose titration scheme will be the same as conducted in Study APD811-003.  Subsequent 
dose escalations will continue until the MTD is determined, with a possible maximum total 
daily dose of 600 mcg (300 mcg BID) if tolerated.  Subjects will be observed for at least 
4 hours after the initial dose of ralinepag, and at each subsequent dose escalation.  AEs, BP, 
and heart rate will be monitored during the observation period.  The observation period may 
be extended based on the judgment of the Investigator.  If deemed necessary by the 
Investigator, the subject may be monitored as an inpatient for the initial dose and/or 
subsequent increases in dose.  The medical monitor should be notified in any instance that 
prolonged observation and/or inpatient monitoring is anticipated or required.   
If a dose is not tolerated, the study drug should be decreased to the previous dose level.  If the 
initial dose of 10 mcg BID is not tolerated, dosing may be decreased to 10 mcg QD. 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 39 
If the initial dose is tolerated (10 mcg BID), then the dose will be increased in the following 
fashion at subsequent visits: 20, 30, 40, 60, 80, 100, 200, and 300 mcg BID.  The dose may be 
escalated to a possible maximum total daily dose of 600 mcg (300 mcg BID) if tolerated. 
Subjects may become symptomatic during the course of dose escalation, and adjustment up 
and/or down may be required to find the optimal dose for any given subject.  Over the 9-week 
Dose Titration Period, there are opportunities to change the dose.  If a particular dose is not 
tolerated, treatment may be reduced to a previous dose as directed by the Investigator.  The 
dose may be decreased for safety/tolerability reasons at any time, but may not be increased 
without assessment in the clinic.  
Table 3 indicates the dosing regimen during the Dose Titration Period. 
Prolonged dosing may result in tolerance to some adverse effects, so that consideration should 
be made to attempt dose escalation if some time (eg, >7 days) has elapsed since the prior dose 
escalation attempt and the 9-week Dose Titration Period is not yet complete. 
In order to simplify dose titration, the 10 mcg strength capsule will be used during the initial 
portion of the dose titration. 
If a subject reaches the highest dose tolerated (stable dose) and no further dose escalations are 
planned, the Dose Titration Period will be considered completed. 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 40 
Table 3 
Possible Dosing Regimen during 9-Week Dose Titration Period 
Dose (mcg) 
Supplied by 
Total daily dose (mcg) 
10 
QD 
1 × 10 mcg 
QD 
10 
10 
BID 
1 × 10 mcg 
BID 
20 
20 
BID 
2 × 10 mcg 
BID 
40 
30 
BID 
3 × 10 mcg 
BID 
60 
40 
BID 
4 × 10 mcg 
BID 
80 
60 
BID 
3 × 20 mcg 
BID 
120 
80 
BID 
4 × 20 mcg 
BID 
160 
100 
BID 
5 × 20 mcg 
BID 
200 
200 
BID 
2 × 100 mcg 
BID 
400 
300 
BID 
3 × 100 mcg 
BID 
600 
Abbreviations: BID, twice daily; QD, once daily 
5.6.1.2 Treatment Period 
Subjects who were on active treatment (ralinepag) in Study APD811-003 will remain on 
current dose and have onsite clinical assessments performed every 3 months until the subject 
is discontinued from the study (see Table 1).  Subjects in the placebo treatment group of 
Study APD811-003 will undergo a Dose Titration Period until a stable MTD is reached (up to 
9 weeks).  At the conclusion of the Dose Titration Period and when a subject reaches the 
highest dose tolerated, the subject will transition directly into the Treatment Period with 
monthly assessments for the first 3 months and then every 3 months. 
The optimal dose achieved for each subject at the end of the Dose Titration Period can be 
maintained throughout the Treatment Period; however, incremental dose increases will also 
be allowed during the Treatment Period at the discretion of the Investigator (as clinically 
indicated) and according to the stepwise titration scheme outlined in Table 4. 
Table 4 indicates the possible IR dosing regimens to be used during the remainder of the 
Treatment Period according to each individual subject’s optimally defined dose. 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 41 
Table 4 
Possible Dosing Regimen during the Treatment Period 
Dose (mcg) 
Supplied by 
Total daily dose (mcg) 
10 
QD 
1 × 0.01 mcg 
QD 
10 
10 
BID 
1 × 0.01 mcg 
BID 
20 
20 
BID 
1 × 0.02 mcg 
BID 
40 
30 
BID 
1 × 0.03 mcg 
BID 
60 
40 
BID 
1 × 0.04 mcg 
BID 
80 
60 
BID 
2 × 0.03 mcg 
BID 
120 
80 
BID 
2 × 0.04 mcg 
BID 
160 
100 
BID 
1 × 0.1 mcg 
BID 
200 
200 
BID 
2 × 0.1 mcg 
BID 
400 
300 
BID 
3 × 0.1 mcg 
BID 
600 
Abbreviations: BID, twice daily; QD, once daily 
5.6.2 
Extended-release Tablets 
5.6.2.1 Formulation Switch and Dose Titration Period 
During the study, all subjects will switch to an XR formulation of ralinepag that will be used 
in Phase 3 studies of ralinepag, per the guidance in Table 5.  The switch to XR ralinepag 
should occur at a regularly scheduled visit, with dose titration to occur, as needed, in 50-mcg 
weekly increments.  Weekly phone contact with the subject will be performed to guide XR 
dose titration to the highest tolerated dose. 
Table 5 
Dose Switching Guidance from Immediate-release to Extended-release 
Ralinepag 
Current IR Dose (mcg; total daily) 
Corresponding XR Dose (mcg) 
<30 
50 EOD 
≥30 to <120 
50 
120 
100 
160 
150 
200 
200 
400 
400 
600 
600 
Abbreviations: EOD, every other day; IR, immediate-release; XR, extended-release 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 42 
5.6.2.2 Treatment Period 
After the dose switch and Dose Titration Period with the XR formulation, subjects will 
continue into the Treatment Period, in which subjects will have an assessment every 
3 months.  With the exception of the difference in ralinepag formulation, this Treatment 
Period will be identical to that which occurred with the IR formulation (Section 5.6.1.1, 
Section 7.2.3). 
The optimal dose achieved for each period during the Formulation Switch and Dose Titration 
Period (Section 5.6.1.1) can be maintained; however, incremental dose changes (uptitration or 
down titration) will also be allowed during the Treatment Period at the discretion of the 
Investigator (as clinically indicated). 
5.7 METHOD OF ASSIGNING SUBJECTS TO TREATMENT GROUPS 
All subjects will receive ralinepag in this study.  Subjects randomized to placebo during Study 
APD811-003 will begin a Dose Titration Period until a stable dose is reached.  Subjects 
randomized to ralinepag during Study APD811-003 will start on the final dose achieved 
during that study.  Subjects who remain on ralinepag at study termination and meet all 
eligibility criteria are eligible to roll into the open-label extension study (ROR-PH-303). 
5.8 RANDOMIZATION AND BLINDING 
Not applicable.  This is an open-label study. 
No re-randomization process is to take place for this study; subjects will retain the 
subject/randomization numbers assigned in Study APD811-003 as subject identifiers in this 
study. 
6 
STUDY PROCEDURES 
Data resulting from procedures collected as part of the subject’s standard of care may be 
collected in addition to the procedures outlined in this section.  This will be outlined 
accordingly in the subject informed consent document and includes the collection of data 
resulting from performance of RHCs performed as standard of care. 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 43 
6.1 INFORMED CONSENT 
The Investigator will obtain and document the informed consent for each subject screened for 
this study.  All subjects will be informed in writing of the nature of the protocol and 
investigational therapy, its possible hazards, and their right to withdraw at any time, and will 
sign a form indicating their consent to participate prior to the initiation of study procedures.  
The subject’s medical record should contain written documentation indicating that informed 
consent was obtained.  The Informed Consent Form (ICF) must be reviewed and approved by 
the Investigator’s designated IRB/IEC and by the Sponsor.  The ICF should include all the 
elements as outlined in ICH Guideline E6. 
6.2 MEDICAL AND SOCIAL HISTORY 
At Baseline, evaluations will include a medical and social history update, to include tobacco, 
alcohol, and caffeine use.  Concomitant medications and concomitant nondrug treatments will 
also be recorded. 
6.3 PHYSICAL EXAMINATION 
Physical examinations will be conducted as per standard clinical practice and should include 
an assessment of each body system, height, and weight.  Physical examinations should be 
performed in a manner that is reasonably consistent from visit to visit.  The physical 
examination performed at the Week 25 Visit of Study APD811-003 will serve as the Baseline 
Visit for Study APD811-007. 
6.4 VITAL SIGNS 
Supine BP, heart rate, body temperature, respiratory rate (RR) and pulse oximetry will be 
measured after the subject has been resting for 5 minutes, according to Table 1 and Table 2, or 
following early termination of the study.  Vital signs will be measured prior to any blood draw 
that occurs at the same time point. 
Proper technique should be utilized during the measurement of BP to include the following: 
• Subjects should be allowed a 5-minute rest period before each assessment.   
• Readings should be taken on the subject’s nondominant arm consistently throughout 
the study.  


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 44 
• The subject’s arm should be bare and supported at heart level. 
• An appropriately sized cuff (cuff bladder encircling at least 80% of the arm) should be 
utilized. 
• The subject’s legs should not be crossed during the evaluation.  
In addition, subjects should be queried concerning caffeine or tobacco use, neither of which is 
permitted within 30 minutes prior to BP measurements. 
It is also critical that standard, consistent definitions of systolic BP and diastolic BP be 
utilized.  Systolic BP is the point at which the first of 2 or more sounds are heard.  Diastolic 
BP is the point before the disappearance of sounds.  The results of the measurement of 
systolic BP and diastolic BP should not be rounded. 
6.5 ELECTROCARDIOGRAPHY 
6.5.1 
ECG Equipment 
Safety ECGs will be recorded from an ECG machine (12-lead).  Safety ECGs will be printed 
and reviewed on site by the Investigator or designee.  Safety ECGs will be captured, recorded, 
and analyzed according to the Centralized ECG Procedure Manual for visits that require 
centralized ECG collection (see Table 1 and Table 2).   
6.5.2 
ECG Acquisition  
Central: The safety ECG equipment will be set according to the procedure manual.  The 
operator will enter certain subject demographic information prior to obtaining the ECG.  
Every attempt will be made to ensure that subject ECG readings throughout the study will be 
obtained from the same machine.  The following subject information will be entered into the 
machine:  
• Subject initials (example: XYZ or X-Z) 
• Subject number (enter the randomization number) 
• Subject sex 
• Subject date of birth (DDMMMYYYY) 
• Study day and time 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 45 
ECGs will be recorded with subjects in the recumbent position and resting.  Subjects will 
have been in this resting position for 10 minutes prior to ECG recording, and the ECG will be 
performed prior to any blood draw that occurs at the same time point. 
In case of baseline tremor, measures will be taken to eliminate this as it may interfere 
significantly with the quality of the interpretation.  Prior to electrode placement, the 
anatomical sites will be prepared to allow for proper skin/electrode interface.  Subjects with 
excessive hair will be dry shaven, as needed. 
Intervals to be provided on the confirmed read for each safety ECG are: RR, PR, QRS, QT, 
QTc, QT interval corrected for Bazett’s formula (QTcB), and QTcF. 
Local: After the last subject enrolled in APD811-007 completes approximately 6 months of 
treatment and a cumulative all-subject data analysis is performed, as outlined in Section 9, 
ECGs will subsequently be conducted locally at the discretion of the Investigator (as clinically 
indicated) during the every 3 (Q3) monthly visits. 
6.5.3 
ECG Assessment 
Baseline ECGs will be compared with the final ECG. 
The Investigator will be responsible for the review and interpretation of safety ECGs on site 
and determining if the ECG is normal, abnormal clinically insignificant, or abnormal 
clinically significant.  Findings will be documented in the Case Report Form (CRF).  This 
information will be used in the ongoing safety review during the conduct of the study. 
6.6 6-MINUTE WALK TEST 
The 6-Minute Walk Test (6MWT) should be conducted according to the guidelines in 
Appendix 1, which have been adapted from the guidelines issued by the American Thoracic 
Society, ATS Statement: Guidelines for the Six-minute Walk Test.
16  Technicians performing 
the test will be trained according to published procedures (Appendix 1).  Tests will be 
performed at approximately the same time of day for each test in order to minimize intra-day 
variability.  The 6MWT performed at the Week 25 Visit of Study APD811-003 will serve as 
the Baseline assessment for Study APD811-007. 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 46 
6.7 WHO/NYHA FUNCTIONAL CLASS ASSESSMENT 
Subjects will be classified according to a system originally developed for heart failure by the 
NYHA and then modified by the WHO for subjects with PAH.
17  The severity of PAH will be 
graded according to the functional status of the subject and assessed at every visit.  The grades 
range from FC I, where the subject's dise
ase does not affect their day-to-day activities, to FC 
IV, where subjects are severely functionally impaired, even at rest (see Appendix 2). 
6.8 RIGHT HEART CATHETERIZATION 
At 1 year (±3 months) after the subject enrolls into APD811-007, an RHC assessment will be 
conducted.  If the subject has been in the APD811-007 study beyond 1 year (±3 months) at 
the time of regulatory/ethics approval of Amendment 2, an RHC assessment will be 
conducted at 2 years (±3 months) instead.  If a subject has been enrolled in APD811-007 for 
more than 2 years at the time of regulatory/ethics approval of Amendment 2, an RHC will be 
performed at the time of those approvals.  It is recommended that every effort should be made 
to take the measurements approximately 4 hours after the last dose of study drug.  An RHC 
should be performed when a subject terminates from the study early if an RHC has not been 
conducted within the previous year. 
The following values will be obtained and recorded: PAP (systolic, diastolic, and mean), heart 
rate, right atrial pressure, PCWP right ventricular pressure and cardiac output, PVR, arterial 
and mixed venous oxygen saturation (if applicable).  Systemic vascular resistance (SVR) will 
be estimated from BP measurements.  Further specifications will be provided in a separate 
study manual. 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 47 
6.9 ASSESSMENT OF CLINICAL WORSENING 
The Investigator will evaluate the subject for potential clinical worsening throughout the 
study.  If clinical worsening is suspected, additional clinic evaluations may be required to 
make a final determination as to whether clinical worsening has been met.  Clinical worsening 
is defined as fulfillment of any 1 of the following criteria (as assessed by change from 
baseline in Study APD811-003: 
• Death, or onset of treatment-emergent AE (TEAE) with a fatal outcome occurring less 
than or equal to 14 days after study treatment discontinuation 
• Hospitalization for worsening PAH, heart-lung or lung transplant, or atrial septostomy 
• The subject requires the addition (or change in dose if applicable) of any of the 
following PAH specific medications: 
• Prostacyclin/prostacyclin analogue (IV, SC, oral, or inhaled)  
• PDE5-I or sGC 
• ERA 
• The combined occurrence of the events listed below:  
• A decrease in 6MWD by at least 20% from baseline, confirmed on two 6MWTs on 
different days 
• Increase (worsening) in WHO/NYHA FC from baseline 
• Appearance of or worsening of signs/symptoms of right heart failure that did not 
respond to optimized oral diuretic therapy 
In cases of clinical deterioration, the Investigator must assess carefully if the deterioration of 
the subject’s condition (eg, worsening FC) is related to the underlying PH or can be explained 
by an alternative cause (eg, transient infection, musculoskeletal disease, surgical or medical 
intervention other than PH related, exacerbation of a concomitant lung disease, lacking 
compliance of medication intake).  Only persistent clinical deteriorations caused by the 
underlying PAH and confirmed as per the above criteria will be considered clinical 
worsening. 
6.10 CLINICAL LABORATORY TESTS 
All details regarding clinical laboratory sample collection, preparation, and shipment are 
included in the laboratory manual provided by the central laboratory for visits that require 
centralized lab collection (see Table 1 and Table 2). 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 48 
In the event of abnormal clinical laboratory values, the physician will make a judgment 
whether or not the abnormality is clinically significant. 
After the last subject enrolled in APD811-007 completes approximately 6 months of 
treatment and a cumulative all-subject data analysis is performed, as outlined in Section 9, 
clinical laboratory tests will subsequently be conducted locally at the discretion of the 
Investigator (as clinically indicated) during the Q3 monthly visits.  Locally collected 
laboratory values that are abnormal and clinically significant will be collected in Sponsor’s 
clinical database along with the reference ranges. 
6.10.1 
Laboratory Parameters 
Clinical laboratory tests will include the following:  
Serum Chemistry 
Albumin (ALB) 
Alkaline phosphatase (ALK-P) 
Alanine aminotransferase (ALT; SGPT) 
Amylase 
Aspartate aminotransferase (AST; SGOT) 
Bicarbonate  
Blood urea nitrogen (BUN) 
Calcium (Ca) 
Chloride (Cl) 
Creatinine  
Creatine kinase and MB subtype (if 
elevated) 
Gamma-glutamyl transferase (GGT) 
Glucose 
Lactate dehydrogenase (LDH) 
Lipase 
Magnesium 
Phosphate  
Potassium (K) 
Sodium (Na) 
Total bilirubin 
Total cholesterol  
Total protein 
Triglycerides 
Hematology  
Hematocrit (Hct) 
Hemoglobin (Hb) 
Mean corpuscular hemoglobin (MCH) 
Mean corpuscular volume (MCV) 
Platelet count 
Red blood cell count (RBC) 
White blood cell count (WBC) with 
differential  
 
Coagulation 
Prothrombin time (PT) 
Activated partial thromboplastin time 
(PTT) 
International normalized ration (INR) 
 
Additional tests  
Serum human chorionic gonadotropin 
(hCG) * 
Brain natriuretic peptide (BNP)*  
N-terminal pro-brain natriuretic peptide 
(NT-proBNP) levels* 
 
* Tests performed at Week 25 Visit of Study APD811-003 will serve as baseline for Study APD811-007. 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 49 
6.10.2 
Urinalysis 
Urinalysis parameters for clinical laboratory tests include the following: 
Appearance 
Occult blood 
Bilirubin 
pH 
Color 
Protein 
Glucose 
Specific gravity 
Ketones 
Urobilinogen 
Leukocyte esterase 
 
 
6.10.3 
Sample Collection, Storage, and Shipping 
Blood samples for hematology, coagulation parameters, serum chemistry, human 
immunodeficiency virus and hepatitis screens, and serum hCG will be collected according to 
the laboratory manual provided by the local or central laboratory and according to the 
schedule of events presented in Table 1 and Table 2. 
6.11 BNP/NT-PROBNP 
As mean PAP increases, so does the brain natriuretic peptide (BNP)/N-terminal pro-brain 
natriuretic peptide (NT-proBNP) level as long as ventricular function is intact.  In idiopathic 
PAH, the BNP/NT-proBNP level is related to functional impairment. 
As BNP/NT-proBNP may be affected by recent exercise, subjects must be allowed to rest for 
a minimum period of 1 hour following arrival at the clinic, prior to obtaining this blood 
sample.  Similarly, this sample must be taken prior to the 6MWT.  This sample should be 
taken with the subject in the same position at all appropriate visits, eg, sitting or 
semi-recumbent.  Detailed instructions about sample collection will be provided in a separate 
sample collection manual. 
After the last subject enrolled in APD811-007 completes approximately 6 months of 
treatment and a cumulative all-subject data analysis is performed, as outlined in Section 9, 
pro-BNP and NT-proBNP testing will subsequently be conducted locally at the discretion of 
the Investigator (as clinically indicated) during the Q3 monthly visits.  Locally collected 
values will be entered into the Sponsor’s clinical database along with the reference ranges. 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 50 
6.12 ADVERSE EVENTS ASSESSMENTS 
AEs will be recorded and reported in accordance with ICH Guideline E6, Good Clinical 
Practice: Consolidated Guidance (1996).  Definitions of AEs and SAEs will be the same as 
those presented in ICH Guideline E2A. 
6.12.1 
Adverse Event Reporting 
Subjects will be instructed that they may report AEs at any time.  All events reported 
following study drug administration will be recorded as TEAEs. 
Monitoring of AEs will be continued up to 30 days after cessation of study drug 
administration.  In the event that an AE is not resolved or stabilized by this time, the Sponsor 
in consultation with the Investigator will decide whether to continue to monitor the AE or 
close-out the event in the database if no further follow-up is necessary. 
For this study, an AE is defined as: “Any untoward medical occurrence in a study subject 
administered any dose of ralinepag and which does not necessarily have to have a causal 
relationship with this treatment.”  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of the study drug, whether or not related to the product. 
AEs can be any of the following: 
• Unfavorable changes in general condition 
• Subjective or objective signs/symptoms 
• Concomitant disease or accidents 
• Clinically relevant adverse changes in laboratory parameters observed in a subject in 
the course of a clinical study 
• Pre-existing conditions which worsen in severity or frequency or which have new 
signs/symptoms associated with them 
AEs will be elicited at the time indicated in the schedule by asking the question, “Since you 
were last asked, have you felt unwell or different from usual in any way?”  Any adverse or 
unexpected events, signs, and symptoms will be fully recorded on the AE Form, including 
details of intensity, onset, duration, outcome, and relationship to the drug as determined by 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 51 
the Investigator.  Whenever possible, a constellation of signs and symptoms should be 
recorded as a unifying diagnosis (eg, self-limited fever, runny nose, cough, and scratchy 
throat should be captured as an upper respiratory infection rather than by the individual signs 
and symptoms).  AEs may also be reported at any time.  The type and duration of follow-up 
of subjects after AEs will be documented. 
6.12.2 
Serious Adverse Events and Expedited Reporting of Adverse Events 
SAEs will be captured from the Study APD811-007 Baseline Visit (Week 25 of Study 
APD811-003) to 30 days after the last dose of study drug and will be monitored until 
resolution or stabilization. 
An SAE is any untoward medical occurrence that at any dose results in the following 
outcomes: 
• Death 
• Is life-threatening 
• Required/prolonged hospitalization 
• Disability/incapacity 
• Congenital anomaly/birth defect 
• Important medical event (see below) 
An important medical event that may not result in death, be life-threatening, or require 
hospitalization may be considered an SAE when, based upon appropriate medical judgment, it 
may jeopardize the subject and may require medical or surgical intervention to prevent 1 of 
the outcomes listed in this definition.  Examples of such a medical event includes allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood 
dyscrasias, or convulsions that do not result in formal hospitalization. 
The following are not considered SAEs despite requiring hospitalization: 
• Pre-existing conditions that, in the opinion of the investigator, did not worsen or 
progress during study participation  
• Routinely scheduled procedures or treatment (eg, routine RHC) 
• Elective procedures that were scheduled prior to study participation (ie, signing of the 
informed consent document) 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 52 
All SAEs, whether or not considered related to study treatment, must be reported to the 
Sponsor contact within 24 hours of becoming aware of the event.  In addition, a completed 
report using the Sponsor’s SAE Report form must be submitted within 24 hours of 
notification to: 
United Therapeutics Global Drug Safety 
Global Fax:  
 
email: 
 
Other situations as defined in ICH Guideline E2A, Clinical Safety Data Management: 
Definitions and Standards for Expedited Reporting (1994), 21 Code of Federal Regulations 
Section 312.32, and EU Volume 10 also qualify for expedited reporting.  In the following 
situations, the process will be as detailed for SAEs above: 
• SAEs which could be associated with the study procedures 
• SAEs and AEs of special interest that could materially influence the benefit-risk 
assessment of a medicinal product, such as a clinically important increase in the rate of 
a serious suspected adverse reaction over that listed in the Investigator’s Brochure 
6.12.3 
Pregnancy 
If a study subject becomes pregnant during participation in this clinical study, site staff must 
notify the sponsor within 24 hours of learning of the pregnancy.  Subjects who become 
pregnant during the study will be discontinued from ralinepag immediately.  Although not 
considered an SAE or AE, pregnancies occurring during the period of ralinepag 
administration until 30 days after the last dose of ralinepag should be reported to the Sponsor 
and IRB/IEC in the same manner as an SAE, using a pregnancy notification form. 
The pregnancy must be followed up to determine outcome (including premature termination) 
and status of mother and child.  Pregnancy complications and elective terminations for 
medical reasons must be reported as an AE or SAE.  Spontaneous abortions must be reported 
as an SAE.  Pregnancies will be followed every trimester through the first well baby visit.  


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 53 
For female partners who become pregnant by male study subjects during the course of the 
study, reasonable efforts will be made to collect information on the partner’s pregnancy 
through the first well baby visit as provided by the male study subject. 
6.12.4 
Assessment of Adverse Event Severity 
The severity of each AE will be assessed at onset by a nurse and/or physician.  When 
recording the outcome of the AE, the maximum severity of the AE experienced will also be 
recorded.  The severity of the AE will be graded according to the Common Terminology 
Criteria for Adverse Events v. 4.0320 definitions listed below: 
Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated. 
Grade 2:  Moderate; minimal, local or noninvasive intervention indicated; limiting age-
appropriate instrumental Activities of Daily Living (ADL)*. 
Grade 3:  Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting self-
care ADL**. 
Grade 4:  Life-threatening consequences; urgent intervention indicated. 
Grade 5:  Death related to AE. 
*  Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing 
money, etc. 
** Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not 
bedridden. 
6.12.5 
Assessment of Adverse Event Relationship to Study Drug  
The relationship of an AE to investigational product(s) will be classified using modified 
WHO criteria (Edwards and Biriell, World Health Organization Collaborating Centre for 
International Drug Monitoring 1994) as follows. 
Related:  a clinical event, including laboratory test abnormality, with a reasonable time 
sequence to administration of the drug, unlikely to be attributed to concurrent disease 
or other drugs or chemicals, and which follows a clinically reasonable response on 
withdrawal (dechallenge).  Rechallenge information is not required to fulfill this 
definition; or an event that could also be explained by concurrent disease or other 
drugs or chemicals where information on drug withdrawal may be lacking or unclear. 
Not related:  a clinical event, including laboratory test abnormality, with sufficient 
evidence to accept that there is no causal relationship to drug administration (eg, no 
temporal relationship to drug administration, because the drug was administered after 
onset of event; investigation shows that the drug was not administered; proof of other 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 54 
cause; etc); or an event with a temporal relationship to drug administration which 
makes a causal relationship improbable, and in which other drugs, chemicals or 
underlying disease provide plausible explanations. 
6.12.6 
Assessment of Adverse Event Outcome 
Outcome of AEs will be defined according to ICH Guideline E2B. 
• Recovered/Resolved 
• Recovering/Resolving 
• Not Recovered/Not Resolved 
• Recovered/Resolved with Sequelae 
• Fatal 
• Unknown 
6.12.7 
Action Taken for Adverse Event 
Action taken for AEs will be documented according to the following: 
• Concomitant medication or other treatment 
• Withdrawal from the study 
6.12.7.1 Action Taken for Study Drug 
Any action taken with study drug will be defined according to ICH Guideline E2B, Data 
Elements for Transmission of Individual Case Safety Reports (1998) and documented in the 
CRF according to the following: 
• Drug Withdrawn 
• Dose Reduced 
• Dose Increased 
• None (not changed) 
• Dose Interrupted 
• Unknown 
• Not Applicable 
6.12.8 
Collection of Extra Laboratory Samples/Investigations 
In the event of a clinically important AE, a suitable sample may be collected for drug assay or 
for additional laboratory tests.  The Investigator must ensure that the sample is properly 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 55 
labeled and stored.  The Investigator and others responsible for the care of the subjects should 
institute any supplementary investigations of significant AEs based on the clinical judgment 
of the likely causative factor.  This may include seeking a further opinion from a specialist in 
the field of the AE.  The company may suggest special tests based on expert advice. 
6.12.9 
Follow-up of Adverse Events Present at Last Scheduled Study Visit 
The AEs present at the last study day (End of Study) that require follow up or a repeat 
laboratory test will be followed up initially for 30 days according to the Sponsor’s.  AEs that 
have not resolved or stabilized at 30 days after the last subject’s last study dose will be 
reviewed on an individual basis to determine whether the database will be locked and 
subsequently updated once the events of ongoing AEs are resolved or whether database lock 
will be held. 
6.13 CONCOMITANT MEDICATION ASSESSMENTS 
All concomitant medications (over-the-counter and prescribed) taken by subjects will be 
recorded in the CRF with indication, start date/time, and stop date/time, if known. 
Subjects are permitted oral disease-specific PAH therapy consisting of an ERA and/or a 
PDE5-I or sGC stimulator, but not all 3.  The on-study addition/substitution of an ERA, 
PDE5-I or sGC stimulator, if on a single such agent at Baseline, or dosage increase for such 
agents is permitted.  In addition to ralinepag, subjects can be prescribed no more than 1 agent 
from the ERA class and 1 from the PDE5-I/sGC stimulator class at any 1 time.  Substitution 
and dose adjustment within each of these classes is permitted.  Subjects should be evaluated 
for the presence of clinical worsening if additional therapy or dose adjustments of current 
therapies are required. 
In addition, the following therapies, which may affect PAH, are permitted and may be 
adjusted in dose as needed:   
• Vasodilators (including calcium channel blockers) 
• Digoxin 
• Spironolactone 
• L-Arginine supplementation 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 56 
Diuretics may be dosed as clinically indicated throughout the study. 
Subjects who require treatment with a prostacyclin/prostacyclin analogue (IV, SC, oral, or 
inhaled), except for acute vasodilator testing during cardiac catheterization, will be 
discontinued from the study. 
6.14 REMOVAL OF SUBJECTS FROM THE STUDY OR STUDY DRUG 
Subjects will be allowed to remain on study drug until marketing approval of ralinepag is 
granted or until the Sponsor discontinues the study.  The study will be terminated early if, in 
the opinion of the Sponsor, Investigator, or IRB/IEC, an unacceptable risk to the safety and 
welfare of subjects is posed by the continuation of the study in light of review of the key 
safety data. 
Subjects will be informed that they are free to withdraw from the study at any time for any 
reason should they so wish.  The Investigator may remove a subject if, in his/her opinion, it is 
in the best interest of the subject.  A subject may be withdrawn from the study for any of the 
following reasons: 
• Clinical worsening, as defined in Section 6.9 
• Deviation/noncompliance with the protocol 
• A serious or intolerable AE occurs 
• The Sponsor or Investigator terminates the study 
• Withdrawal of consent - any subject may withdraw his/her consent from the study at 
any time.  The Investigator should make a reasonable attempt to document the specific 
reason why consent is withdrawn. 
6.14.1 
Handling of Withdrawals 
Although a subject is not obliged to give his/her reason for withdrawing prematurely, the 
Investigator will make a reasonable effort to obtain the reason while fully respecting the 
subject’s rights.  If there is a medical reason for discontinuation, the subject will remain under 
the supervision of the study physician until in satisfactory health.  Reasonable efforts will be 
made to contact a subject who fails to attend any follow-up appointments, in order to ensure 
that he/she is in satisfactory health. 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 57 
If a subject is prematurely discontinued from this study, every attempt will be made to follow 
the End of Study Procedures described in Section 7. 
In addition, all subjects will be contacted at the time of Study APD811-007 closure to assess 
vital (mortality) status.  The vital status follow-up contact of subjects will depend on local 
regulations or specific agreement with the subject and Investigator. 
6.15 ALLOWABLE VISIT AND PROCEDURE WINDOWS 
A ±3-day window is allowed for study visits and procedures during the Dose Titration Period, 
Treatment Period, and End of Study and Follow-up Visits, with the exception of the Q3 
Month Visits during the Treatment Period, which are allowed a ±5-day window. 
7 
STUDY ACTIVITIES 
7.1 SCREENING VISIT 
Given that this study serves as an extension to Study APD811-003, an independent Screening 
Visit is not required.  In order for subjects to be eligible for this study, they must have 
completed Study APD811-003 as planned or have been assigned to placebo and discontinued 
for clinical worsening and fulfill the eligibility criteria outlined in Section 4. 
Subjects who have an interest in participating in this study should be properly consented prior 
to completing the Week 25 Visit in Study APD811-003.  This is to include a detailed oral 
presentation of the nature, purpose, risks, and requirements of the study in addition to 
receiving detailed written information.  Each subject should have adequate opportunity to ask 
the appropriate person of the clinical staff (ie, Investigator or designee) presenting the study 
about any aspect of the study.  Once the subject is satisfied that he/she is willing to participate 
in the study, he/she will be asked to sign the study ICF.  The clinical personnel obtaining 
written consent from the subject will also sign the form to confirm consent has been obtained.  
Once signed, the Investigator will retain the original for the subject’s study records and 
provide the subject with a signed copy.  The Investigator will verify that informed consent has 
been obtained from each subject prior to admission into the study and prior to the subject 
undergoing any study-related procedures.  If it is standard practice at the site to conduct a few 
general noninvasive study procedures (ie, medical/social history, collection of concomitant 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 58 
medications, etc) before a subject can be considered for a specific study, the study center must 
have a written SOP detailing the procedure, and also ensure that each subject signs a general 
consent prior to undergoing the general procedures. 
7.2 STUDY PROCEDURES 
7.2.1 
Baseline Study Procedures – All Subjects  
Subjects who meet all the entry criteria and are eligible for the study will report to the clinical 
study unit to confirm eligibility for the study and complete all Baseline procedures and 
receive study drug and instructions.  The study drug will be given in the morning at the study 
site during the Baseline Visit.  
7.2.1.1 Pre-baseline Procedures 
All Week 25 measurements from Study APD811-003 will serve as Baseline assessments for 
Study APD811-007.  
Placebo-treated subjects who discontinued prematurely from Study APD811-003 due to 
clinical worsening are permitted to enroll in APD811-007 provided that all end of study 
procedures are performed per the ADP811-003 protocol.  For these subjects, the time of the 
clinical worsening event that led to early termination in Study APD811-003 will serve as the 
Baseline time point for clinical worsening in APD811-007. 
Any unresolved AE from Study APD811-003 will be carried forward and recorded. 
7.2.1.2 Baseline Procedures 
• Medical history (partial history, to update findings from Study APD811-003)  
• Physical exam1 
• 12-lead ECG
1 
• Clinical laboratory tests (to include hematology, coagulation parameters, serum 
chemistry, and urinalysis)
1 
• Serum pregnancy test (women only)1 
• Vital signs1 
• 6MWT1 
• BNP/NT-proBNP
1 
• Assessment of clinical worsening  


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 59 
• WHO/NYHA FC assessment
1 
• Record AEs
1 
• Record concomitant medications1 
1 Taken from Week 25 Visit in Study APD811-003 
7.2.2 
Study Procedures – for Immediate-release Dose Titration Period (Study 
APD811-003 Placebo Subjects) 
Visits after Baseline should occur weekly for each escalation of study drug dose.  There 
should be 1 study visit per week during the Dose Titration Period.  Beyond the weekly visit, 
any additional visit during the Dose Titration Period will be documented as an ‘unscheduled’ 
visit. 
If a subject reaches a stable MTD and no further dose escalations are planned, the Dose 
Titration Period will be considered completed and will be followed by monthly assessments 
for the first 3 months and then every 3 months until the subject is discontinued from the study, 
Sponsor termination of the study, or the last subject enrolled completes approximately 
6 months of treatment with ralinepag. 
7.2.2.1 Pre-dose Procedures for Dose Titration Period Visits (Study APD811-003 
Placebo Subjects) 
• Vital signs according to Table 2 
• Safety ECG at Weeks 1 to 9 according to Table 2 
• Assessment of clinical worsening 
• WHO/NYHA FC assessment  
• Clinical laboratory tests (to include hematology, coagulation parameters, serum 
chemistry, and urinalysis) at Weeks 2, 5, and 9 
• Serum hCG pregnancy test (females only) at Week 5 
• Record AEs 
• Record concomitant medications 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 60 
7.2.2.2 Post-dose Procedures for Dose Titration Period Visits (Study APD811-003 
Placebo Subjects) 
• Study drug administration  
• Vital signs: every hour through the first 4 hours 
• Safety ECG 2 hours post-dose at Weeks 1 to 9 according to Table 2 
• Record AEs 
• Record concomitant medications 
7.2.3 
Study Procedures for the Treatment Period – All Subjects (For Both 
Immediate-release and Extended-release Formulations) 
7.2.3.1 Study Procedures M1-M3 (Study APD811-003: Placebo-treated Subjects) Q3 
Months (Study APD811-003: Placebo- and Ralinepag-treated Subjects; 
Subjects who Switched to the XR Formulation) 
• Safety ECG according to Section 6.5.2 and Table 1 and Table 2. 
• Clinical laboratory tests (to include hematology, coagulation parameters, serum 
chemistry, and urinalysis) according to Section 6.10 and Table 1 and Table 2. 
• Serum hCG pregnancy test (females only) according to Section 6.10 and Table 1 and 
Table 2 
• Vital signs 
• Study drug administration 
• 6MWT 
• BNP/NT-proBNP according to Section 6.10 and Table 1 and Table 2 
• Assessment of clinical worsening 
• WHO/NYHA FC assessment 
• Dose escalation assessment according to according to Table 1 and Table 2 
• Record AEs 
• Record concomitant medications 
7.2.3.2 Study Procedures - Year 1 or Year 2 
• RHC – according to Table 1 and Table 2 (see study RHC manual) 
7.2.3.3 Switch to XR Ralinepag and Dose Titration 
At 1 of the regular quarterly visits, as outlined in Section 7.2.3.1, in addition to the regularly 
scheduled procedures, subjects will be given new dosing cards with an XR formulation of 
ralinepag.  Dose-switching will occur as outlined in Table 5, and titration will occur as 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 61 
described in Section 5.6.2.1 via weekly telephone calls until the next regularly scheduled 
quarterly visit, at which time the subject will resume procedures described in Section 7.2.3.1. 
7.2.4 
End of Study Visit – All Subjects 
• Physical exam  
• Safety ECG according to Section 6.5.2 and Table 1 and Table 2 
• Clinical laboratory tests (to include hematology, coagulation parameters, serum 
chemistry, and urinalysis) according to Section 6.10 and Table 1 and Table 2 
• Serum hCG pregnancy test (females only) 
• Vital signs  
• 6MWT 
• Assessment of clinical worsening 
• WHO/NYHA FC assessment  
• Record AEs 
• Record concomitant medications 
7.2.5 
28-day Follow-up – All Subjects 
• WHO/NYHA FC assessment  
• Assessment of clinical worsening 
• Record AEs 
• Record concomitant medications 
8 
DATA MANAGEMENT 
8.1 DATA COLLECTION 
All data (ECGs, clinical laboratory data, and all other study-related data) will be collected 
according to the Sponsor or CRO’s SOPs. 
Upon database lock, to include resolution of all queries, the CRO (if applicable) will provide 
statistical analysis software transfer datasets to the Sponsor and biostatistician for analysis 
using secure electronic data transfer per the Sponsor’s specifications. 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 62 
8.2 DATA CODING 
8.2.1 
Adverse Events 
AEs will be coded using the MedDRA and tabulated, including categorical information of 
interest, such as onset and resolution times, time of onset relative to dose, severity at onset, 
maximum severity, causal relationship to study drug, and action taken.  Whenever possible, a 
constellation of signs and symptoms should be recorded as a unifying diagnosis (eg, 
self-limited fever, runny nose, cough, and scratchy throat should be captured as an upper 
respiratory infection rather than by the individual signs and symptoms).  As there is no 
Screening Period in this study and subjects will enter the study on active treatment, all AEs 
that occur after the first dose of study drug will be considered treatment emergent. 
8.2.2 
Concomitant Medications 
Due to the variability in how medications are recorded, a standard naming convention is 
required in order to tabulate these data effectively.  A common method of standardization is to 
categorize medications by their Preferred Term.  In order to do this, medications will be coded 
using the WHO Drug Dictionary.  
9 
PLANNED STATISTICAL METHODS 
After the last subject enrolled in APD811-007 completes approximately 6 months of 
treatment, a cumulative all-subject data analysis will be performed. 
The statistical analysis of the data obtained from this study will be the responsibility of the 
Sponsor.  Details of the statistical analyses will be included in a separate Statistical Analysis 
Plan, which will be finalized before database lock.  If, after the database has been locked, 
changes are made to the pre-specified Statistical Analysis Plan, the changes will be listed 
along with an explanation as to why they occurred in the Clinical Study Report. 
9.1 ANALYSIS POPULATIONS 
Safety Population: 
This population will include all subjects who received at least 1 dose of the study drug in this 
extension study. 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 63 
Modified Intent-to-treat Population: 
The analyses of all efficacy variables will use the Modified Intent-to-Treat Population.  This 
population consists of all subjects randomized who received at least 1 dose of study drug in 
the extension study, have a baseline measurement, and have at least 1 measurement after entry 
into the extension study.  The Last Observation Carried Forward approach will be used to 
impute missing values.  
9.2 STATISTICAL METHODS 
9.2.1 
Safety Analysis 
Safety is the primary analysis for this extension study.  All subjects who receive study drug in 
the extension study will be evaluated for safety.  Long-term safety and tolerability of 
ralinepag will be assessed by clinical and statistical review of all relevant safety parameters, 
including AEs, laboratory values, vital signs, and ECG findings. 
9.2.1.1 Demographics and Baseline Characteristics 
All baseline subject characteristics for demographic data (age, height, weight, race), medical 
history (abnormalities only), physical examination (abnormalities only), and concomitant 
medications at entry in Study APD811-003 and also at entry in this extension study will be 
listed for all subjects.  Demographic data will be summarized and tabulated.  Continuous 
variables will be summarized using number of observations, mean, standard deviation, 
median, minimum, and maximum.  Frequencies and percentages will be reported for all 
categorical data. 
9.2.1.2 Adverse Events 
The AEs will be coded using the most current MedDRA and tabulated, including categorical 
information of interest, such as onset and resolution times, time of onset relative to dose, 
severity at onset, maximum severity, causal relationship to study drug, and action taken.  
All AEs will be listed by subject and will be summarized and expressed in terms of maximum 
severity and relationship to study drug. 
9.2.1.3 Physical Examinations 
Physical examination results (abnormalities only) will be collected. 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 64 
9.2.1.4 Vital Signs 
Individual vital sign measurements will be listed by measurement time and summarized using 
descriptive statistics.  Summary statistics will also be provided for change from baseline in 
vital sign measurements.  
9.2.1.5 Clinical Laboratory Values 
Individual laboratory values will be listed by visit and summarized using descriptive statistics.  
Summary statistics will also be provided for change from Baseline in laboratory values.  Shift 
tables from baseline to the last extension study visit will also be produced for the laboratory 
assessments based on the categories of Low, Normal, and High.  A clinically significant 
change from baseline may be recorded as an AE if deemed appropriate by the Investigator or 
Sponsor. 
9.2.1.6 Safety ECGs 
Individual ECG values will be listed by visit and summarized using descriptive statistics.  
Intervals to be provided for each ECG are RR, PR, QRS, QT, QTc, QTcB, and QTcF.  ECGs 
will be compared with the baseline ECG.  Any clinically significant change from baseline 
may be recorded as an AE if deemed appropriate by the Investigator or Sponsor. 
9.2.2 
Statistical Analyses of Efficacy Measurements 
Efficacy analyses are considered as secondary for this extension study.  The time to clinical 
worsening will be summarized.  Estimation and 95% confidence intervals for 
within-treatment change from baseline in 6MWD, WHO/NYHA FC assessment, and main 
hemodynamic parameters will also be performed.  Baseline is defined as the Day 1 pre-dose 
measurements from Study APD811-003.  A secondary analysis using a definition of Baseline 
as Day 1 of Study APD811-007 will also be performed. 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 65 
10 
REGULATORY REQUIREMENTS 
10.1 PRE-STUDY DOCUMENTATION 
The Sponsor must receive the following documentation prior to initiation of the study: 
• Protocol signature page signed by the Investigator 
• FDA form 1572 signed by the Investigator 
• Curriculum vitae of the Investigator, updated within 2 years 
• Current medical licenses for the Investigator 
• Copy of the IRB/IEC approval letter for the study and approved ICF 
• IRB/IEC Membership List 
Additional country-specific documentation may be required per international regulatory 
authorities.  Documents should be sent to the Sponsor at the following address: 
United Therapeutics Corporation  
55 T.W. Alexander Drive  
Research Triangle Park, NC 27709, USA 
 
10.2 INVESTIGATOR OBLIGATIONS 
The Investigator is responsible for ensuring that all study site personnel and other study staff 
members adhere to all applicable FDA and/or applicable country regulations and guidelines 
regarding clinical studies, including guidelines for GCP (including the archiving of essential 
documents), both during and after study completion.  The Investigator will be responsible for 
the subject’s compliance to the study protocol.  The Investigator is responsible for providing 
the Sponsor an adequate final report shortly after he/she completes participation in the study, 
in accordance with ICH Guidelines E6, E2A, and E8. 
10.3 SUBJECT CONFIDENTIALITY 
All information obtained during the conduct of the study with respect to the subjects’ state of 
health will be regarded as confidential.  This is detailed in the written information provided to 
the subject.  An agreement for disclosure of any such information will be obtained in writing 
and is included in both copies of the ICF signed by the subject.  The study data shall not be 
disclosed to a third party without the written consent of the Sponsor. 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 66 
10.4 INFORMED CONSENT 
According to ICH Guideline E6, Good Clinical Practice: Consolidated Guidance (1996), the 
Investigator will obtain and document informed consent for each subject screened for this 
study.  All subjects will be informed in writing of the nature of the protocol and 
investigational therapy, its possible hazards, and their right to withdraw at any time, and will 
sign a form indicating their consent to participate prior to the initiation of study procedures.  
The subject’s medical record should contain written documentation indicating that informed 
consent was obtained.  The ICF must be reviewed and approved by the Investigator’s 
designated IRB/IEC and by the Sponsor.  The ICF should include all the elements as outlined 
in Section 4.8.10 of ICH Guideline E6. 
10.5 INSTITUTIONAL REVIEW BOARD 
This protocol and relevant supporting data are to be submitted to the appropriate IRB/IEC for 
review and approval before the study can be initiated.  Amendments to the protocol will also 
be submitted to the IRB/IEC prior to implementation of the change.  The Sponsor must 
receive a letter documenting the IRB/IEC approval prior to initiation of the study.  The 
Investigator is also responsible for informing the IRB/IEC of the progress of the study and for 
obtaining annual IRB/IEC renewal.  The IRB/IEC must be informed at the time of completion 
of the study and should be provided with a summary of the results of the study by the 
Investigator.  The Investigator must notify the IRB/IEC in writing of any SAE or any 
unexpected AE according to ICH guidelines. 
11 
PROTOCOL MANAGEMENT AND ADMINISTRATIVE CONSIDERATIONS 
11.1 STUDY DOCUMENTATION 
The Investigator has the responsibility of maintaining a comprehensive and centralized filing 
system containing all study-related documentation.  These files must be available for 
inspection by the Sponsor, representatives of the Sponsor, the IRB/IEC, and regulatory 
authorities (ie, FDA or international regulatory authorities) at any time, and should consist of 
the following elements: 
• Subject files, containing the completed CRFs, supporting source documentation from 
the medical records, including laboratory data and the ICF 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 67 
• Regulatory files, containing the protocol with all amendments and Investigator 
signature pages, copies of all other regulatory documentation, and all correspondence 
between the site and the IRB/IEC and Sponsor; and drug accountability files, 
including a complete account of the receipt and disposition of the study drug. 
Records are to be available for 2 years after marketing application approval, or if the 
application is not approved or never submitted, 2 years after the last shipment and delivery of 
the material and the appropriate competent regulatory authorities are notified.  The Sponsor 
will provide written notification when it is appropriate for the Investigator to discard the 
study-specific documents referenced above. 
11.2 PROTOCOL INTERPRETATION AND COMPLIANCE 
To ensure accurate interpretation and implementation of the study, the procedures and 
endpoints defined in the protocol will be carefully reviewed by the Investigator prior to the 
time of study initiation.  The Sponsor and Investigator will follow all reasonable means to 
resolve any differences of opinion of matters of eligibility, toxicity, and other endpoints.  In 
the event that a resolution cannot be reached, 1 or both parties may seek to terminate the study 
following the provisions outlined in the Clinical Trials Agreement. 
11.3 STUDY MONITORING 
The Sponsor or a contracted monitor will visit the study center periodically to monitor 
adherence to the protocol, compliance with ICH guidelines, adherence to applicable FDA 
and/or applicable country regulations, and the maintenance of adequate and accurate clinical 
records.  CRFs will be reviewed to ensure that key safety and efficacy data are collected and 
recorded as specified by the protocol.  The monitor will be permitted to access subjects’ 
complete medical records, laboratory data, and other source documentation as needed to 
monitor the study appropriately. 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 68 
12 
REFERENCE LIST 
1. Hata AN, Breyer RM.  Pharmacology and signaling of prostaglandin receptors: 
multiple roles in inflammation and immune modulation.  Pharmacol Ther.  
2004;103(2):147-166. 
2. McLaughlin VV, Shillington A, Rich S.  Survival in primary pulmonary hypertension: 
the impact of epoprostenol therapy.  Circulation.  2002 September 17;106(12):1477-
1482. 
3. McGoon MD, Miller DP.  REVEAL: a contemporary US pulmonary arterial 
hypertension registry.  Eur Respir Rev.  2012;21(123):8-18. 
4. Archer SL, Weir EK, Wilkins MR.  Basic science of pulmonary arterial hypertension 
for clinicians: new concepts and experimental therapies.  Circulation.  
2010;121(18);2045-2066. 
5. European Medicines Agency (EMEA).  Guideline on the Clinical Investigations of 
Medicinal Products for the Treatment of Pulmonary Arterial Hypertension (Doc. Ref. 
EMEA/CHMP/EWP/356954/2008) London, 22 October 2009. 
6. Tuder RM, Cool CD, Geraci MW, et al.  Prostacyclin synthase expression is decreased 
in lungs from patients with severe pulmonary hypertension.  Am J Respir Crit Care 
Med.  1999;159(6):1925-32. 
7. Barst RJ, Rubin LJ, Long WA, et al.  A comparison of continuous intravenous 
epoprostenol (prostacyclin) with conventional therapy for primary pulmonary 
hypertension.  The Primary Pulmonary Hypertension Study Group.  N Engl J Med.  
1996;334(5):296-302. 
8. Simonneau G, Robbins IM, Beghetti M, et al.  Updated clinical classification of 
pulmonary hypertension.  J Am Coll Cardiol.  2009;54(1 Suppl):S43-S54. 
9. Humbert M, Sitbon O, Chaouat A, et al.  Pulmonary arterial hypertension in France: 
results from a national registry.  Am J Respir Crit Care Med.  2006;173(9):1023-1030. 
10. Peacock AJ, Murphy NF, McMurray JJ, et al.  An epidemiological study of pulmonary 
arterial hypertension.  Eur Respir J.  2007;30(1):104-109. 
11. Badesch DB, Raskob GE, Elliott CG, et al.  Pulmonary arterial hypertension: baseline 
characteristics from the REVEAL Registry.  Chest.  2010;137(2):376-87.  
12. Galiè N, Corirs PA, Frost A, et al.  Updated treatment algorithm of pulmonary arterial 
hypertension.  J Am Coll Cardiol.  2013;62(25, Suppl D):60-72. 
13. Orenitram
® [Prescribing Information], Research Triangle Park, NC: United 
Therapeutics Corp.; December 2013. 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 69 
14. Tyvaso® [Prescribing Information], Research Triangle Park, NC: United Therapeutics 
Corp.; July 2009. 
15. McLaughlin VV, Archer SL, Badesch DB, et al.  ACCF/AHA 2009 expert consensus 
document on pulmonary hypertension a report of the American College of Cardiology 
Foundation Task Force on Expert Consensus Documents and the American Heart 
Association developed in collaboration with the American College of Chest 
Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension 
Association.  J Am Coll Cardiol.  2009;53(17):1573-1619. 
16. ATS Committee on Proficiency Standards for Clinical Pulmonary Function 
Laboratories.  ATS Statement: Guidelines for the Six-Minute Walk Test.  Am J Respir 
Crit Care Med.  2002;166(1):111-117. 
17. Galiè N, Hoeper MM, Humbert M, et al.  Guidelines for the diagnosis and treatment of 
pulmonary hypertension.  Eur Heart J.  2009;30:2493-537. 
18. Fijalkowska A, Kurzyna M, Torbicki A, et al.  Serum N-terminal brain natriuretic 
peptide as a prognostic parameter in patients with pulmonary hypertension.  Chest.  
2006;129:1313-21. 
19. Habib G, Torbicki A.  The role of echocardiography in the diagnosis and management 
of patients with pulmonary hypertension.  Eur Respir Rev.  2010;19(118):1-12. 
20. Common Terminology Criteria for Adverse Events v4.03 (CTCAE). Publish Date: 
June 14, 2010. Accessed October 2010. 
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-
14_QuickReference_5x7.pdf 
 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 70 
Appendix 1 Guidelines for 6-Minute Walk Test 
(Adapted from American Thoracic Society (ATS) Statement: Guidelines for the Six-Minute 
Walk Test. [ATS Statement 2002]) 
Location 
The 6MWT should be performed indoors preferably, along a long, flat, straight, hallway with 
a hard surface that is seldom traveled.  The walking course must be 15 to 50 meters in 
length.  Turnaround points should be marked with a brightly colored cone.  A starting line, 
which marks the beginning and end of each lap, should be marked on the floor with brightly 
colored tape.  If possible, the subject should use the same 6MWT location for each test and 
same pair of shoes. 
Safety Issues 
1. Testing should be performed in a location where a rapid, appropriate response to an 
emergency is possible.  The appropriate location of a crash cart should be determined 
by the physician supervising the facility. 
2. Supplies that should be available include oxygen, sublingual nitroglycerine, aspirin, 
and albuterol (eg, a beta agonist by metered dose inhaler or nebulizer).  A telephone or 
other means should be in place to enable a call for help. 
3. The technician should be certified in cardiopulmonary resuscitation with a minimum 
of Basic Life Support and American Health Association-approved cardiopulmonary 
resuscitation course (or equivalent).  Advanced cardiac life support certification is 
desirable.  Training, experience, and certification in related health care fields 
(registered nurse, registered respiratory therapist, certified pulmonary function 
technician, etc) are also desirable.  A certified individual should be readily available to 
respond if needed. 
4. Physicians are not required to be present during all tests.  The physician ordering the 
test or supervising a laboratory physician may decide whether physician attendance at 
a specific test is required. 
Reasons for immediately stopping a 6MWT include the following: (1) chest pain, (2) 
intolerable dyspnea, (3) leg cramps, (4) staggering, (5) diaphoresis, and (6) pale or ashen 
appearance. 
Technicians must be trained to recognize these problems and the appropriate responses.  If a 
test is stopped for any of these reasons, the subject should sit or lie supine as appropriate 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 71 
depending on the severity or the event and the technician’s assessment of the severity of the 
event and the risk of syncope. 
Equipment in the Vicinity 
1. O2 saturation equipment + forehead probes. 
2. Countdown timer or stopwatch. 
3. Mechanical lap counter. 
4. Two small cones to mark the turnaround points. 
5. A chair that can be easily moved along the walking course. 
6. Worksheets. 
7. A source of oxygen. 
8. Telephone. 
9. Automated electronic defibrillator. 
Subject Preparation 
1. Comfortable clothing should be worn. 
2. Appropriate shoes for walking should be worn preferably the same pair for each test. 
3. A subject should use his or her usual walking aids during the test (cane, walker, etc). 
4. The subject’s usual medical regimen should be continued and study drug taken in the 
morning before the commencement of the 6MWT. 
5. A light meal is acceptable before early morning or early afternoon tests. 
6. Subjects should not have exercised vigorously within 2 hours of beginning the test. 
Measurements 
1. Repeat testing should be performed about the same time of day to minimize intra-day 
variability. 
2. A “warm-up” period before the test should not be performed. 
3. The subject should sit at rest in a chair, located near the starting position, for at least 
10 minutes before the test starts.  During this time, check for contraindications and 
make sure that clothing and shoes are appropriate.  Record all pertinent information 
surrounding the test (ie, starting location, length of hallway, direction the subject will 
be walking, time of test, subject’s general condition/feeling on the day of the test, and 
any other physical or medical information that may potentially influence the results of 
the test). 
4. Subjects who require supplemental oxygen must breathe a stable oxygen dose for at 
least 15 minutes prior to the measurement of SpO2 and until the end of the 6MWT (see 
below for SpO2 requirements).  It is critical that if oxygen was utilized during the 
screening 6MWTs, that it be utilized during all subsequent on-study tests and that it is 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 72 
delivered in the same manner with the same flow.  Note whether the oximeter signal 
quality is acceptable. 
5. Set the lap counter to 0 and the time to 6 minutes.  Assemble all necessary equipment 
(lap counter, timer, worksheets, etc.) and move to the starting point. 
6. Instruct the subject as follows: 
The object of this test is to walk as far as possible for 6 minutes.  You will walk back and 
forth in this hallway.  Six minutes is a long time to walk, so you will be exerting yourself.  
You will probably get out of breath or become exhausted.  You are permitted to slow 
down, to stop, and to rest as necessary.  You may lean against the wall while resting, but 
resume walking as soon as you are able. 
You will be walking back and forth around the cones.  You should pivot briskly around the 
cones and continue back the other way without hesitation.  Now I’m going to show you.  
Please watch the way I turn without hesitation. 
Demonstrate by walking one lap yourself.  Walk and pivot around a cone briskly. 
Are you ready to do that?  I am going to use this counter to keep track of the number of 
laps you complete.  I will click it each time you turn around at this starting line.  
Remember that the object is to walk AS FAR AS POSSIBLE for 6 minutes, but don’t run or 
jog. 
Start now or whenever you are ready. 
7. Position the subject at the starting line.  You should also stand near the starting line 
during the test.  Do not walk with the subject.  As soon as the subject starts to walk, 
start the timer. 
8. Do not talk to anyone during the walk.  Use an even tone of voice when using the 
standard phrases of encouragement.  Watch the subject.  Do not get distracted and lose 
count of the laps.  Each time the participant returns to the starting line, click the lap 
counter once (or mark the lap on the worksheet).  Let the participant see you do it. 
Exaggerate the click using body language, like using a stopwatch at a race. 
After the first minute, tell the subject the following (in even tones): You are doing well.  You 
have 5 minutes to go. 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 73 
When the timer shows 4 minutes remaining, tell the subject the following: Keep up the good 
work.  You have 4 minutes to go. 
When the timer shows 3 minutes remaining, tell the subject the following: You are doing well.  
You are halfway done. 
When the timer shows 2 minutes remaining, tell the subject the following: Keep up the good 
work.  You have only 2 minutes left. 
When the timer shows 1 minute remaining, tell the subject: You are doing well.  You have 
only 1 minute to go. 
Do not use other words of encouragement (or body language) to speed the subject up. 
If the subject stops walking during the test and needs a rest, say this: You can lean against the 
wall if you would like: then continue walking whenever you feel able.  Do not stop the timer.  
If the subject stops before the 6 minutes are up and refuses to continue (or you decide that 
they should not continue), wheel the chair over for the subject to sit on, discontinue the walk 
and note on the worksheet the distance, the time stopped, and the reason for stopping 
prematurely. 
When the timer is 15 seconds from completion, say this: In a moment I’m going to tell you to 
stop.  When I do, just stop right where you are and I will come to you. 
When the time rings (or buzzes), say this: Stop!  Walk over to the subject.  Consider taking 
the chair if they look exhausted.  Mark the spot where they stopped by placing a bean bag or a 
piece of tape on the floor. 
9. Record the number of laps from the counter (or tick marks on the worksheet). 
10. Record the additional distance covered (the number of meters in the final partial lap) 
using the markers on the wall as distance guides (or use a tape measure).  Calculate the 
total distance walked, rounding to the nearest meter, and record it on the worksheet. 
11. Congratulate the subject on good effort and offer a drink of water. 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 74 
CONTRAINDICATIONS  
Absolute contraindications for the 6MWT include the following: unstable angina during the 
previous month and myocardial infarction during the previous month.  Relative 
contraindications include a resting heart rate of more than 120, a systolic BP of more than 
180 mmHg, and a diastolic BP of more than 100 mmHg.  
Subjects with any of these findings should be referred to the physician ordering or supervising 
the test for individual clinical assessment and a decision about the conduct of the test.  The 
results from a resting electrocardiogram done during the previous 6 months should also be 
reviewed before testing.  Stable exertional angina is not an absolute contraindication for a 
6MWT, but subjects with these symptoms should perform the test after using their antiangina 
medication, and rescue nitrate medication should be readily available.  
Rationale 
Subjects with the previously mentioned risk factors may be at increased risk for arrhythmias 
or cardiovascular collapse during testing.  However, each subject determines the intensity of 
their exercise, and the test (without electrocardiogram monitoring) has been performed in 
thousands of older persons and thousands of subjects with heart failure or cardiomyopathy 
without SAEs.  The contraindications listed previously here were used by study Investigators 
based on their impressions of the general safety of the 6MWT and their desire to be prudent, 
but it is unknown whether AEs would occur if such subjects performed a 6MWT; they are, 
therefore, listed as relative contraindications. 


United Therapeutics Corporation  
ADP811-007 Protocol Amendment 4 
 
Ralinepag 
Version Date 15 May 2019 
Confidential 
Page 75 
Appendix 2 Functional Classification of Pulmonary Hypertension Modified After The 
New York Heart Association Functional Classification According to the 
WHO 1998 
World Health Organization functional assessment classification  
Class I:  Subjects with pulmonary hypertension (PH) but without resulting limitation of 
physical activity.  Ordinary physical activity does not cause undue dyspnea or 
fatigue, chest pain, or near syncope. 
Class II:  Subjects with PH resulting in slight limitation of physical activity.  They are 
comfortable at rest.  Ordinary physical activity causes undue dyspnea or 
fatigue, chest pain, or near syncope. 
Class III:  Subjects with PH resulting in marked limitation of physical activity.  They are 
comfortable at rest.  Less than ordinary activity causes undue dyspnea or 
fatigue, chest pain, or near syncope. 
Class IV:  Subjects with PH with inability to carry out any physical activity without 
symptoms.  These subjects manifest signs of right-heart failure.  Dyspnea 
and/or fatigue may even be present at rest.  Discomfort is increased by any 
physical activity. 
Adapted from guidelines for the diagnosis and treatment of pulmonary hypertension17 
 

SAP_001.pdf: 
United Therapeutics Corp. 
APD811-007 Statistical Analysis Plan 
 
Ralinepag 
 
Page 1 
Document Type: 
Statistical Analysis Plan 
Protocol / Study No.: 
APD811-007 
Finalization Date: 
12-JAN-2021 
Total Number of Pages 
including Appendices: 
19 
Classification: 
Confidential 
 
 
Title: 
An Open-label Extension Study of APD811-003 in Patients  
with Pulmonary Arterial Hypertension 
 
Author: 
 
 
CONFIDENTIAL AND PROPRIETARY, UNITED THERAPEUTICS CORP. 
All content contained herein is confidential and proprietary information of 
United Therapeutics Corp. and shall not be disclosed in whole or in part except as permitted by 
a signed contract with United Therapeutics Corp.  
© 2021 United Therapeutics Corp. 
 


United Therapeutics Corp. 
APD811-007 Statistical Analysis Plan 
 
Ralinepag 
Version 12 JAN 2021 
CONFIDENTIAL 
Page 2 
TABLE OF CONTENTS 
TABLE OF CONTENTS .......................................................................................................... 2 
ABBREVIATIONS AND DEFINITIONS................................................................................ 4 
1 PREFACE............................................................................................................................ 5 
2 STUDY OBJECTIVES AND ENDPOINTS ....................................................................... 5 
2.1 
OBJECTIVES ................................................................................................................. 5 
2.2 
ENDPOINTS ................................................................................................................... 5 
3 STUDY DESIGN ................................................................................................................. 6 
4 RANDOMIZATION ........................................................................................................... 6 
5 INTERIM ANALYSIS ........................................................................................................ 7 
6 SAMPLE SIZE CONSIDERATIONS ................................................................................ 7 
7 ANALYSIS POPULATIONS.............................................................................................. 7 
8 GENERAL CONSIDERATIONS FOR DATA ANALYSES ............................................ 7 
8.1 
EXAMINATION OF SUBGROUPS .............................................................................. 8 
8.2 
PREMATURE DISCONTINUATION AND MISSING DATA ................................... 8 
8.3 
MULTIPLE COMPARISONS AND MULTIPLICITY ............................................... 8 
8.4 
ASSESSMENT WINDOWS ........................................................................................... 8 
9 STUDY POPULATION ...................................................................................................... 9 
9.1 
SUBJECT ACCOUNTABILITY ................................................................................... 9 
9.2 
ELIGIBILITY CRITERIA ............................................................................................ 9 
9.3 
OTHER DESCRIPTIONS OF STUDY POPULATION ............................................ 10 
 
Demographics ........................................................................................................... 10 
 
Baseline Characteristics ........................................................................................... 10 
 
PAH History ............................................................................................................. 10 
 
Concomitant Medications ........................................................................................ 10 
 
Ralinepag Dosing...................................................................................................... 11 
10 EFFICACY ANALYSES .................................................................................................. 11 
10.1 TIME TO CLINICAL WORSENING ......................................................................... 11 
10.2 6-MINUTE WALK TEST ............................................................................................ 11 
10.3 WHO FUNCTIONAL CLASS ..................................................................................... 12 
10.4 HEMODYNAMICS ...................................................................................................... 12 
10.5 BNP/NT-proBNP .......................................................................................................... 12 
11 SAFETY ANALYSES ....................................................................................................... 13 
11.1 ADVERSE EVENTS .................................................................................................... 13 
11.2 DEATHS ....................................................................................................................... 13 
11.3 CLINICAL LABORATORY TESTS .......................................................................... 14 
11.4 VITAL SIGNS .............................................................................................................. 14 
11.5 SAFETY ECG ............................................................................................................... 15 
12 CHANGES FROM ANALYSIS PLANNED IN THE PROTOCOL ............................... 15 
13 APPENDICES ................................................................................................................... 16 


United Therapeutics Corp. 
APD811-007 Statistical Analysis Plan 
 
Ralinepag 
Version 12 JAN 2021 
CONFIDENTIAL 
Page 3 
13.1 LIST OF TABLES ........................................................................................................ 16 
13.2 LIST OF LISTINGS ..................................................................................................... 18 
13.3 LIST OF FIGURES ...................................................................................................... 19 
 


United Therapeutics Corp. 
APD811-007 Statistical Analysis Plan 
 
Ralinepag 
Version 12 JAN 2021 
CONFIDENTIAL 
Page 4 
ABBREVIATIONS AND DEFINITIONS 
Abbreviation 
Definition 
6MWT 
6-Minute Walk Test 
6MWD 
6-Minute Walk Distance 
AE 
Adverse event 
BNP 
B-Type natriuretic peptide 
ECG 
Electrocardiogram 
FC 
Functional Class 
NT-proBNP 
N-Terminal pro-brain natriuretic peptide 
PAH 
Pulmonary arterial hypertension 
PT 
Preferred Term 
PVR 
Pulmonary vascular resistance 
RHC 
Right heart catheterization 
SAE 
Serious adverse event 
SOC 
System Organ Class 
WHO 
World Health Organization 
 


United Therapeutics Corp. 
APD811-007 Statistical Analysis Plan 
 
Ralinepag 
Version 12 JAN 2021 
CONFIDENTIAL 
Page 5 
1 
PREFACE 
This document describes the planned analyses for Study APD811-007, as presented in the study 
protocol.  This plan is based on the original APD811-007 protocol dated 17 June 2014 and 
subsequent protocol amendments (latest version Protocol Amendment 4 dated 15 May 2019), 
and provides further details of the analyses presented in the protocol as well as additional 
planned analyses.  Additional post-hoc or unplanned analyses that are not defined in this 
Statistical Analysis Plan may be performed.  Such analyses will be documented in the Clinical 
Study Report. 
2 
STUDY OBJECTIVES AND ENDPOINTS 
2.1 
OBJECTIVES 
The study objectives are to: 
• Evaluate the long-term safety and tolerability of ralinepag in subjects with World Health 
Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) who have 
completed Study APD811-003. 
• Evaluate the effect of ralinepag in subjects with WHO Group 1 PAH who completed 
Study APD811-003, as determined by the incidence of clinical worsening. 
• Evaluate changes from baseline in 6-Minute Walk Distance (6MWD), WHO/New York 
Hearth Association Functional Class (FC), and hemodynamics. 
2.2 
ENDPOINTS 
The safety endpoints are as follows: 
• Adverse events (AEs) 
• Clinical laboratory parameters 
• Vital signs 
• Electrocardiograms (ECGs) 
Efficacy will be assessed by: 
• Clinical worsening 
• 6-Minute Walk Test (6MWT)  
• WHO FC  
• Hemodynamics 


United Therapeutics Corp. 
APD811-007 Statistical Analysis Plan 
 
Ralinepag 
Version 12 JAN 2021 
CONFIDENTIAL 
Page 6 
• B-type natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide 
(NT-proBNP) 
3 
STUDY DESIGN 
APD811-007 is a Phase 2, multicenter, open-label extension study to determine the long-term 
safety and tolerability of ralinepag in subjects with WHO Group 1 PAH who have completed the 
Phase 2 study, APD811-003, or who were assigned to placebo and were discontinued for clinical 
worsening.  Subjects must also meet eligibility criteria for participation in APD811-007.  All 
subjects enrolled in the study will receive open-label treatment with ralinepag.  Subjects on 
active treatment in the parent study (APD811-003) will remain on current dose and have onsite 
clinical assessments performed every 3 months until the subject is discontinued from the study.  
Subjects in the placebo treatment group of the parent study will undergo a dose-titration period 
until a stable, maximum tolerated dose is reached (up to 9 weeks).  The titration will be followed 
by a treatment period during which monthly onsite clinic assessments will be performed for the 
first 3 months and then every 3 months until the subject is discontinued from the study or the 
study is terminated.  
The APD811-007 Baseline Visit corresponds to the Study Termination Visit of the parent study 
and occurs prior to initiation of study drug. 
Study APD811-007 is being discontinued by the Sponsor to combine all subjects still ongoing 
treatment across the program into 1 Phase 3, open-label, long-term extension study (ROR-PH-
303). 
4 
RANDOMIZATION 
Study APD811-007 is not randomized.  All subjects will receive ralinepag during the open-label 
study, regardless if the subjects were randomized to and received ralinepag or placebo in the 
parent study.  However, some analyses are based on the treatment group (ralinepag or placebo) 
in the parent study. 


United Therapeutics Corp. 
APD811-007 Statistical Analysis Plan 
 
Ralinepag 
Version 12 JAN 2021 
CONFIDENTIAL 
Page 7 
5 
INTERIM ANALYSIS 
An interim analysis was performed in September 2018 to evaluate the long-term safety and 
tolerability for all subjects who had received treatment in APD811-007 for at least 1 year.  In 
addition, the objective of the interim analysis was to support proposed Phase 3 studies.  Interim 
analysis was intended to take place in lieu of final study analysis; however, with the 
discontinuation of Study APD811-007, final analysis is being conducted to serve the protocol 
objectives with the entirety of study data. 
6 
SAMPLE SIZE CONSIDERATIONS 
No formal sample size calculation has been conducted.  All eligible subjects from the parent 
study may be enrolled into the open-label extension study. 
7 
ANALYSIS POPULATIONS 
All available data from all subjects will be used as detailed in this analysis plan. 
The Safety Population will include any subject who received ralinepag at any time during the 
course of the APD811-007 study.  All analyses are based on the Safety Population. 
8 
GENERAL CONSIDERATIONS FOR DATA ANALYSES 
All data included in each data cut will be listed.  In general, listings will be sorted by subject 
number and scheduled assessment (if applicable) or the visit date.  Listings will include 
assessment date, assessment time (if available), and study day.  The study day is calculated as the 
assessment date minus the date of the first ralinepag dose in the APD811-007 study.  For data 
collected on a fixed schedule, the assessment identifier will also be included on the listing. 
In general, the data will be summarized by scheduled (nominal) visits.  For all presentations of 
the summary tables, the data will be presented by treatment group of the parent study and 
overall. 
For continuous variables, the summary statistics will include the mean, standard deviation, 
median, minimum, and maximum.  Minimums and maximums will be expressed using the level 
of precision in which the variable was collected.  All other statistics will be rounded, using an 
additional decimal point.  For discrete variables, summaries will include the frequency and 


United Therapeutics Corp. 
APD811-007 Statistical Analysis Plan 
 
Ralinepag 
Version 12 JAN 2021 
CONFIDENTIAL 
Page 8 
percent in each category.  Percentages will be rounded to 1 decimal point.  Whenever practical, 
categories of discrete variables will be ordered and labeled as they appear in the electronic Case 
Report Form, and all categories represented on the electronic Case Report Form will be included 
in summaries, even when they do not apply to any subjects in the study. 
8.1 
EXAMINATION OF SUBGROUPS 
Exploratory subgroup analyses will be performed as data permit. 
8.2 
PREMATURE DISCONTINUATION AND MISSING DATA 
A subject may voluntarily withdraw or be withdrawn from the study by the Investigator at any 
time for reasons including the following: 
• Clinical worsening 
• Deviation/noncompliance with the protocol 
• A serious or intolerable AE occurs 
• The Sponsor or Investigator terminates the study, or 
• Withdrawal of consent – any subject may withdraw his/her consent from the study at any 
time.  The Investigator should make a reasonable attempt to document the specific reason 
why consent is withdrawn. 
All available data from all subjects in the Safety Population, as defined in Section 7, will be used 
as detailed in this analysis plan.  Missing data will not be imputed. 
8.3 
MULTIPLE COMPARISONS AND MULTIPLICITY 
No multiple comparison adjustments are planned for analysis of APD811-007. 
8.4 
ASSESSMENT WINDOWS 
For efficacy and safety assessments, baseline is defined as the last measurement prior to the first 
dose of ralinepag in the APD811-007 study. 
Summary analyses will usually be based on the scheduled (nominal) visits with no visit windows 
applied.  If appropriate, hemodynamic parameters will only be summarized by the Baseline and 
post-Baseline Visits of APD811-007.  


United Therapeutics Corp. 
APD811-007 Statistical Analysis Plan 
 
Ralinepag 
Version 12 JAN 2021 
CONFIDENTIAL 
Page 9 
9 
STUDY POPULATION 
9.1 
SUBJECT ACCOUNTABILITY 
A listing of subject disposition and ralinepag exposure will include the subject number, treatment 
group in the parent study, first and last ralinepag dose date/time in the APD811-007 study, date 
completed/discontinued the study, study drug exposure (weeks), reason for discontinuation, and 
any other details regarding reason for discontinuation.  The summary of subject accountability 
will include the number (percent) of subjects who completed the study without early termination, 
the number of subjects who completed ralinepag treatment by each visit achieved, number of 
subjects who discontinued ralinepag treatment, and the reason for discontinuation.  This 
summary will be provided by treatment group in the parent study and overall. 
Ralinepag exposure and the total patient-years of ralinepag exposure will be summarized by the 
treatment group in the parent study and overall.  Duration of treatment will be further 
characterized by weeks on the immediate-release and extended-release formulations. 
In addition, for subjects who were in the ralinepag group of the parent study, exposure to 
ralinepag in the parent study will be combined into the APD811-007 study.  The overall 
exposure to ralinepag across both the parent study and the APD811-007 study will be 
summarized. 
9.2 
ELIGIBILITY CRITERIA 
The listing of entry criteria for all subjects will include whether the subject rolled over from the 
previous study, each subject’s treatment group in the parent study, status regarding meeting all 
eligibility criteria (yes/no), and an explanation if all eligibility criteria are not met.  The summary 
of entry criteria will include the number (percent) of subjects who met all eligibility criteria and 
the number (percent) of subjects who did not meet all eligibility criteria by treatment group in the 
parent study and overall. 
In addition, a listing will be provided for protocol deviations.  The listing will include the subject 
number, deviation date, deviation type, deviation severity, and deviation description by treatment 
group in the parent study. 


United Therapeutics Corp. 
APD811-007 Statistical Analysis Plan 
 
Ralinepag 
Version 12 JAN 2021 
CONFIDENTIAL 
Page 10 
9.3 
OTHER DESCRIPTIONS OF STUDY POPULATION 
 
Demographics  
The listing of subject demographics will be organized by treatment group in the parent study, and 
will include subject number, country, assessment date, date of birth, age (years), sex, ethnicity, 
race, height, weight, and body mass index.  The age will be calculated based on the first 
ralinepag dose date in the APD811-007 study.  The summary of demographics will include 
descriptive statistics for age (years), height, weight, and body mass index at first dose of 
ralinepag, where weight and height are obtained from the parent study; and categorical 
summaries for age (<65 and ≥65 years), sex, ethnicity, and race. 
 
Baseline Characteristics 
Baseline characteristics including 6MWD, 6MWD category (≤440 m versus >440 m), pulmonary 
vascular resistance (PVR), WHO FC, BNP, and NT-proBNP will be summarized by treatment 
group in the parent study and overall.  Baseline measures are defined as the last measurement 
prior to the first ralinepag dose in the APD811-007 study. 
 
PAH History 
The listing of PAH history will be organized by treatment group in the parent study, and will 
include the subject number, the date of initial PAH diagnosis, number of years since PAH 
diagnosis, PAH classification, WHO FC at Baseline, 6MWD at Baseline, PVR at Baseline, PAH 
disease specific concomitant medication, and background PAH medication name.  The number 
of years since PAH diagnosis will be calculated based on the first ralinepag dose date in the 
APD811-007 study.  The summary of PAH history will include descriptive statistics for years 
since PAH diagnosis and categorical summaries for PAH classification and PAH disease specific 
concomitant medication at randomization in the parent study. 
 
Concomitant Medications 
The listing of concomitant medications will be organized by treatment group in the parent study 
and will include the verbatim term, WHO Drug Dictionary standard name, the date started, date 
discontinued, and the condition(s) treated/indication(s).  Summaries will be provided for 
medications ongoing from the parent study and for those added in the APD811-007 study.  Each 
summary will be provided by treatment group in the parent study and overall and will include the 


United Therapeutics Corp. 
APD811-007 Statistical Analysis Plan 
 
Ralinepag 
Version 12 JAN 2021 
CONFIDENTIAL 
Page 11 
number (percent) of subjects reporting each medication by WHO Drug Dictionary medication 
name. 
 
Ralinepag Dosing  
In the APD811-007 study, a listing and a summary will be provided for ralinepag dosing.  The 
listing will be organized by treatment group in the parent study, and will include the subject 
number, visit date, titration action, actual dose, immediate-release or extended-release, and total 
daily dose. 
The ralinepag dose will be summarized by analysis visit.  The summary will also include the 
number (percent) of subjects in each dose category by treatment group in parent study and 
overall. 
10 
EFFICACY ANALYSES 
10.1 
TIME TO CLINICAL WORSENING 
Time to the first event of clinical worsening will be calculated and listed.  Time to clinical 
worsening is calculated from the treatment start date in APD811-007 to the first occurrence of 
clinical worsening.  For subjects who do not experience clinical worsening, it will be censored at 
the last record date of clinical worsening assessment or end of study, whichever is latest. 
Summaries and analyses will be performed for time to clinical worsening.  Kaplan-Meier 
estimate will be provided along with the corresponding p-value using log-rank test.  In addition, 
hazard ratio, 95% confidence interval, and p-value will be provided using the Cox proportional 
hazard model.  A Kaplan-Meier plot will also be provided. 
10.2 
6-MINUTE WALK TEST 
The listing of the 6MWT will be organized by treatment group in the parent study, and will 
include the subject number, visit, assessment date/time (day), last ralinepag dose date/time (day), 
the last ralinepag dose (micrograms), hours from last ralinepag dose to 6MWT, 6MWD results, 
and use of supplemental oxygen.  The summaries of 6MWD will be provided by treatment group 
in the parent study for each visit.  The summaries will include descriptive statistics for 6MWD 
and the change from baseline.  Baseline is defined as the last 6MWD measured prior to the first 
dose of ralinepag in the APD811-007 study. 


United Therapeutics Corp. 
APD811-007 Statistical Analysis Plan 
 
Ralinepag 
Version 12 JAN 2021 
CONFIDENTIAL 
Page 12 
10.3 
WHO FUNCTIONAL CLASS 
WHO FC information will be listed by treatment group in the parent study and will include the 
subject number, visit, assessment date (day), and WHO FC.  The summaries of the WHO FC will 
be provided by treatment group in the parent study.  The summaries will include descriptive 
statistics for measurements at each visit and the shift from baseline.  Baseline is defined as the 
last WHO FC assessed prior to the first dose of ralinepag in the APD811-007 study. 
10.4 
HEMODYNAMICS 
Right heart catheterization (RHC) measurements will be obtained at 1 year (±3 months) after a 
subject enrolls into Study APD811-007.  If the subject has been in Study APD811-007 beyond 1 
year (±3 months) at the time of regulatory/ethics approval of Protocol Amendment 2, an RHC 
assessment will be conducted at 2 years (±3 months) instead.  If a subject has been enrolled in 
Study APD811-007 more than 2 years at the time of regulatory/ethics approval, an RHC 
assessment will be performed at the time of those approvals. 
Hemodynamic values will be listed by treatment group in the parent study.  The summaries of 
the hemodynamic values will be provided by treatment group in the parent study.  The 
summaries will include descriptive statistics for measurements at each visit and the change from 
baseline values.  The summary statistics may include the geometric mean, interquartiles, and 
ratio to the baseline.  Baseline is defined as the last hemodynamic values assessed prior to the 
first dose of ralinepag in the APD811-007 study.  The mean plot of PVR may be generated 
across time with each parent treatment group. 
10.5 
BNP/NT-proBNP 
BNP and NT-proBNP will be measured at Baseline and then every 3 months during the 
treatment period.  BNP and NT-proBNP will be listed by treatment group in the parent study.  
The summaries of the BNP and NT-proBNP will be provided by treatment group in the parent 
study.  The summaries will include descriptive statistics for measurements at each visit and the 
change from baseline values.  The summary statistics may include the geometric mean, 
interquartiles, and ratio to the baseline.  Baseline is defined as the last BNP and NT-proBNP 
assessed prior to the first dose of ralinepag in the APD811-007 study. 


United Therapeutics Corp. 
APD811-007 Statistical Analysis Plan 
 
Ralinepag 
Version 12 JAN 2021 
CONFIDENTIAL 
Page 13 
11 
SAFETY ANALYSES 
11.1 
ADVERSE EVENTS 
AEs are captured from the time the Informed Consent Form is signed.  AEs that are ongoing at 
the parent study Termination Visit are recorded as continuing AEs in the APD811-007 study.  
All AEs with an onset date on or after the first dose of ralinepag in the APD811-007 study or 
AEs ongoing from the parent study will be included in data listings and summaries. 
The AEs will be coded using the Medical Dictionary for Regulatory Activities, and all 
summaries will utilize the Preferred Term (PT) and/or System Organ Class (SOC).  All AEs and 
serious adverse events (SAEs) will be organized by treatment group in the parent study and listed 
by subject number, including onset date (day) and time, stop date (day) and time, verbatim term, 
corresponding PT and SOC, seriousness, severity, relationship to study drug, action taken with 
study drug, and outcome. 
The overall summary of AEs includes the number of subjects with any AE, the number of 
subjects with any study drug-related AEs, the number of subjects with AEs leading to study drug 
withdrawal, the number of subjects with any SAEs, the number of subjects with any severe AEs, 
and the number of subjects with any study drug-related severe AEs. 
The summaries of AEs by SOC and PT will be provided by treatment group in the parent study 
and overall.  The summaries of AEs, SAEs, severe AEs, AEs related to ralinepag, SAEs related 
to ralinepag, and AEs leading to permanent discontinuation of ralinepag will include the number 
(percent) of subjects and number of events for each reported PT. 
The summary of AEs adjusted for length of ralinepag exposure will include the number (percent) 
of subjects and number of events for each reported PT, as well as the number of events per 
patient-years of exposure. 
11.2 
DEATHS 
All deaths will be listed (including those occurring within 30 days of the last ralinepag dose) by 
subject number and will include the first ralinepag dose date in Study APD811-007, last 
ralinepag dose date in Study APD811-007, date of death, and cause of death.  The summary of 
deaths will be presented by the parent study and overall and will include the number (percent) of 


United Therapeutics Corp. 
APD811-007 Statistical Analysis Plan 
 
Ralinepag 
Version 12 JAN 2021 
CONFIDENTIAL 
Page 14 
subjects who died (including those within 30 days of study participation) and their causes of 
death. 
11.3 
CLINICAL LABORATORY TESTS 
The laboratory data will be listed by subject number and treatment group in the parent study, 
including all hematology and clinical chemistry parameters by visit.  The listings will include the 
collection date/times (day), laboratory test, and results.  The normal laboratory reference ranges 
will be included in the listings.  A designation for low (L) or high (H) will be included for those 
laboratory values that are outside the relevant normal range.  The listing of urinalysis and 
coagulation will also be presented by subject number and treatment group in the parent study and 
will include each scheduled and unscheduled urinalysis assessment.  The laboratory sample 
collection date/time (day), laboratory test, normal range, designation for high or low, and 
analysis visit will be provided for each assessment, as well as the result of the test. 
For hematology, clinical chemistry, and coagulation parameters, the original values and their 
changes from baseline (defined as the last measurement prior to the first dose of ralinepag in the 
APD811-007 study) will be summarized for each analysis visit by the treatment group in the 
parent study and overall.  Shift tables for hematology and clinical chemistry will also be 
provided.  For urinalysis results, the number (percent) of subjects within each category will be 
summarized for all analysis visits by treatment group in the parent study and overall. 
Pregnancy test results for female subjects will be organized by treatment group in the parent 
study and listed by subject number and did the subject become pregnant during the study 
(yes/no). 
11.4 
VITAL SIGNS 
The vital sign data will be listed by subject number and treatment group in the parent study for 
each visit by the assessment date/time (day), heart rate, systolic blood pressure, diastolic blood 
pressure, and respiratory rate.  The original measures and their changes from baseline (defined as 
the last measurement prior to the first ralinepag dose in the APD811-007 study), and descriptive 
statistics will be summarized for all analysis visits by the treatment group in the parent study and 
overall. 


United Therapeutics Corp. 
APD811-007 Statistical Analysis Plan 
 
Ralinepag 
Version 12 JAN 2021 
CONFIDENTIAL 
Page 15 
11.5 
SAFETY ECG 
Individual ECG values will be listed by treatment group in the parent study and visit.  They will 
be summarized using descriptive statistics.  Intervals to be provided for each ECG are: 
respiratory rate, PR, QRS, QT, QT interval corrected, QT interval corrected for Bazett’s formula, 
and QT interval corrected for Fridericia’s formula.  Post-baseline ECGs will be compared with 
the baseline ECG.  Summary statistics will also be provided for change from baseline in ECG 
values.  The baseline value is defined as the last measurement prior to the first ralinepag dose in 
APD811-007. 
12 
CHANGES FROM ANALYSIS PLANNED IN THE PROTOCOL 
For the final analysis, the following changes have been made to the analyses that are described in 
the protocol: 
• Safety Population will be used for all summaries (protocol Section 9.1 specifies modified 
Intent-to-Treat Population for efficacy analyses). 
• The protocol separated the primary objective and secondary objectives.  The analyses 
will be based on efficacy and safety, not specifically separating the primary and 
secondary objectives. 
• Protocol Section 6.2 states medical and social history would be updated at Baseline in 
Study APD811-007.  These updates were not collected. 
• No imputation will be performed for missing efficacy values (protocol Section 9.1 
specifies Last Observation Carried Forward imputation for efficacy missing values). 
• Baseline for change from baseline in efficacy values will be the APD811-007 baseline 
value (protocol Section 9.2 specifies the Day 1 pre-dose measurement in Study APD811-
003 as the main baseline, with Day 1 of Study APD811-007 as baseline for a secondary 
analysis). 
• Follow-up vital status (mortality) was not collected. 
• Local results of BNP/NT-proBNP are not available. 


United Therapeutics Corp. 
APD811-007 Statistical Analysis Plan 
 
Ralinepag 
Version 12 JAN 2021 
CONFIDENTIAL 
Page 16 
13 
APPENDICES 
13.1 
LIST OF TABLES 
Table titles suggested here may be altered or edited as appropriate by the clinical data 
programmers while maintaining the original intent of the summary. 
Table Number 
Table Title 
14.1.1 
Summary of Subject Accountability 
14.1.2 
Summary of Ralinepag Exposure 
14.1.3 
Summary of Ralinepag Exposure in APD811-003 and APD811-007 Studies  
14.1.4 
Summary of Demographics 
14.1.5 
Summary of Baseline Characteristics 
14.1.6 
Summary of PAH History 
14.1.7 
Summary of Study Entry Criteria 
14.1.8 
Summary of Ralinepag Dosing 
14.1.9.1 
Summary of Concomitant Medications Ongoing from the Previous Study 
14.1.9.2 
Summary of Concomitant Medications Added in Study APD811-007 
14.2.1.1 
Summary and Analysis of Clinical Worsening 
14.2.1.2 
Summary of 6MWD (meters) by Visit  
14.2.1.3 
Summary of WHO Functional Class by Visit 
14.2.1.4  
Summary of Hemodynamics by Visit 
14.2.1.5  
Summary of BNP and NT-proBNP by Visit 
14.3.1.1 
Overall Summary of Adverse Events 
14.3.1.2 
Summary of Adverse Events by System Organ Class and Preferred Term 
14.3.1.3 
Summary of Adverse Events by Preferred Term 
14.3.1.4 
Summary of Serious Adverse Events by Preferred Term 
14.3.1.5 
Summary of Severe Adverse Events by Preferred Term 
14.3.1.6 
Summary of Serious Adverse Events Related to Ralinepag by Preferred Term 
14.3.1.7 
Summary of Adverse Events Related to Ralinepag by Preferred Term 
14.3.1.8 
Summary of Adverse Events Leading to Permanent Discontinuation of Study 
Drug by Preferred Term 
14.3.1.9 
Summary of Adverse Events Adjusted for Length of Ralinepag Exposure 
14.3.2.1 
Listing of Deaths 
14.3.2.2 
Summary of Deaths 
14.3.2.3 
Listing of Serious Adverse Events 
14.3.4.1 
Summary of Hematology Data 
14.3.4.2 
Summary of Hematology Shifts from Baseline 
14.3.4.3 
Summary of Clinical Chemistry Data 
14.3.4.4 
Summary of Clinical Chemistry Shifts from Baseline 
14.3.4.5 
Summary of Urinalysis Data 
14.3.4.6 
Summary of Coagulation Data 


United Therapeutics Corp. 
APD811-007 Statistical Analysis Plan 
 
Ralinepag 
Version 12 JAN 2021 
CONFIDENTIAL 
Page 17 
Table Number 
Table Title 
14.3.4.7  
Summary of Vital Signs 
14.3.4.8 
Summary of Electrocardiogram Parameters 
 


United Therapeutics Corp. 
APD811-007 Statistical Analysis Plan 
 
Ralinepag 
Version 12 JAN 2021 
CONFIDENTIAL 
Page 18 
13.2 
LIST OF LISTINGS 
Listing titles suggested here may be altered or edited as appropriate by the clinical data 
programmers while maintaining the original intent of the listing. 
Appendix Number 
Listing Title 
16.2.1 
Subject Disposition and Study Drug Exposure 
16.2.2.1 
Entry Criteria 
16.2.2.2 
Protocol Deviations 
16.2.4.1 
Demographics 
16.2.4.2 
PAH History  
16.2.4.3 
Concomitant Medications  
16.2.5 
Ralinepag Dosing 
16.2.6.1 
Clinical Worsening Events 
16.2.6.2 
6-Minute Walk Test  
16.2.6.3 
WHO Functional Class for PAH 
16.2.6.4 
Hemodynamics Variables  
16.2.6.5 
BNP and NT-proBNP 
16.2.7 
Adverse Events 
16.2.8.1 
Laboratory Results – Clinical Chemistry 
16.2.8.2 
Laboratory Results – Hematology 
16.2.8.3 
Laboratory Results – Urinalysis 
16.2.8.4  
Laboratory Results – Coagulation 
16.2.8.5 
Pregnancy Test Results (Female Subjects Only) 
16.2.8.6 
Vital Signs 
16.2.8.7 
Electrocardiogram Parameters 
 


United Therapeutics Corp. 
APD811-007 Statistical Analysis Plan 
 
Ralinepag 
Version 12 JAN 2021 
CONFIDENTIAL 
Page 19 
13.3 
LIST OF FIGURES 
Figure titles suggested here may be altered or edited as appropriate by the clinical data 
programmers while maintaining the original intent of the figure. 
Figure Number 
Figure Title 
14.2.1 
Kaplan-Meier Plot of Time to Clinical Worsening by Treatment Group in 
Parent Study 
14.2.2 
Plot of Pulmonary Vascular Resistance